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Abstract
The human papillomavirus (HPV) is a prevalent virus and the most common sexually transmitted
infection (STI) worldwide. Nearly 80 million people, approximately one in four, are currently
infected in the United States (US). Given that HPV infections affects over 20 million Americans
with possible life-threatening consequences, the importance of adhering to the recommended
two-dose or three-dose vaccination series has a significant impact on cancer prevention.
Research studies have suggested that adolescents and young adults are at an increased risk of
STIs and low HPV vaccination rates. For this integrative review, the target population was
adolescents to young adults, ages 9-26 years. Education on the benefits of HPV vaccination has
been key to increasing vaccination rates. Healthcare costs associated with preventing and treating
HPV-related conditions in the US have been at least $8.0 billion annually. HPV vaccines are the
most effective and safest way to protect against HPV and a significant element in reducing future
adverse health outcomes related to HPV. The Gardasil 9 vaccine is the recommended HPV
vaccine, and it protects against the most high-risk strands of HPV, strands 16 and 18, plus
several other high-risk strands that cause HPV-associated cancers and other abnormalities. The
Centers for Disease Control and Prevention (CDC) recommends that males and females between
the ages of 9 and 26 be offered the Gardasil vaccine to combat HPV-related infections and
cancers. The primary purpose of this integrative review was to examine the impact of the vaccine
provider in relation to gaining the patient's acceptance and initiation of the HPV vaccine.
Implications from this project may influence healthcare organizations to make HPV Gardasil
vaccination a priority.
Keywords: HPV, HPV vaccine, adolescents, prevention, education strategies, primary
care providers (PCP)
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Section One: Formulating the Review Question
The Centers for Disease Control and Prevention ([CDC]:2019a) reports that human
papilloma virus (HPV) infection is the most common sexually transmitted infection (STI), with
nearly 80 million people currently infected in the US as of 2017. HPV-associated cancers occur
in parts of the body where the HPV is located: the cervix, vagina, vulva, penile area, anus, and
oropharynx. These cancers have become increasingly prevalent in the US. Health organizations
like the CDC and Advisory Committee on Immunization Practices (ACIP) promote numerous
strategies to increase HPV vaccination rates globally.
Over 45,300 HPV-associated cancers occur yearly in the US, including 25,400 among
women and 19,900 among men (CDC, 2020). HPV infection risk increases when young adults
are not adequately vaccinated with the HPV vaccine recommended during their adolescent
period before a first sexual encounter. The CDC recommends HPV vaccination for males and
females starting as early as nine years of age and extending until 26 years. The CDC considers
the HPV vaccination series a preventive measure in decreasing certain HPV strains that cause
cancer.
The number of cancer cases related to HPV infection can be eliminated by a patient
receiving the recommended two-dose or three-dose HPV vaccine; however, many young adults
fail to vaccinate in adolescence at the recommended age per CDC's ACIP committee. The HPV
vaccine has been proven to be safe and effective against infections caused by the HPV virus;
however, HPV vaccination rates have remained low, prompting healthcare providers to evaluate
numerous campaign strategies to improve vaccination rates (CDC, 2020).
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Background
As shown through various studies, research data on HPV infection acknowledges, that
HPV infection is the most prevalent STI among late teens and young adults in the US. In 2018,
the CDC reported that over 43 million Americans were infected with HPV and that there were 13
million cases of newly infections (CDC, 2021). The ACIP recommends males and females ages
9-14 years be vaccinated with two doses of the HPV Gardasil 9 vaccine and that individuals’
ages 15-26 years be vaccinated with the three-dose series. In 2018, the HPV vaccine three-dose
series completion rates averaged 56.8% for adolescent females and 51.8% for adolescent males
(Elam-Evans et al., 2020). Completion of the HPV dose series before becoming sexually active
is recommended by ACIP as a best practice. However, those who have become sexually active
should, nonetheless, be vaccinated if they meet the age requirement.
Treatment costs of STIs and associated complications can be upwards of 16 billion
dollars annually, of which HPV infections make up 755 million dollars (Chesson et al., 2021).
With HPV infection being the most common STI, it is imperative to discover effective means to
increase vaccination rates to improve the virus's complications. Vaccines licensed for use in the
US are nine-valent (Gardasil), quadrivalent (Gardasil), and bivalent (Cervarix); however, only
Gardasil 9 is currently available in the US. Gardasil 9 covers the most high-risk strains of HPV,
strains 16 and 18, plus several other high-risk strains that cause HPV-associated cancers.
Gardasil 9 has been proven to be safe and effective in preventing cervical cancer and other HPVrelated problems, thus decreasing healthcare costs related to HPV complications and saving lives
(Meites et al., 2019).
Statistics indicate that anogenital HPV infection is the most common STI among young
adults and a leading causative agent in many types of HPV-related cancers. HPV vaccination
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coverage among adolescents aged 13 to 17 years with greater than one dose of HPV vaccine
increased from 68.1% in 2018 to 71.5%, and the percentage of adolescents who vaccinations
were up-to-date increased from 51.1% to 54.2% in 2019 (Elam-Evans et al., 2020). The National
Immunization Survey-Teen survey reported in 2019 that HPV vaccination rates had improved
from earlier years; however, disparities existed, making HPV vaccination a priority among
adolescents and young adults.
Defining Concepts and Variables
The conceptual definition of the risk for HPV-associated cancers among young adults
was the lack of HPV vaccination uptake recommended by the CDC for adolescents and young
adults ages 9-26. The variables consisted of strategies used to accept, initiate, and complete the
HPV vaccination series among children and young adults. Concepts for this integrative review
consisted of providers’ role in promoting the HPV vaccine along with HPV vaccination initiation
and compliance among the population identified for this review.
Rationale for Conducting the Review
Various research studies have suggested a knowledge deficit about HPV infection,
prevention of HPV infection, and perceived safety and efficacy of the HPV vaccine are the main
reasons for adolescents and young adults not being vaccinated. Treatment costs of HPV
infections could cause a substantial burden on the healthcare delivery system in the future. With
the number of HPV-infected young adults, healthcare leaders may need to develop and
implement an HPV vaccination strategy to increase HPV vaccination and vaccination completion
rates among children and young adults.
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Purpose Statement
The purpose of this integrative review was to examine the impact of the provider in
relation to gaining a patient's acceptance of the HPV vaccine and its subsequent initiation. The
expected outcome of the integrative review was 1) identification of evidence-based strategies in
the literature healthcare providers use to gain patient’ acceptance of HPV vaccine initiation and
2) ability to provide recommendations for future practice. Additionally, the project leader sought
to identify best practices that providers can employ to assist with patient compliance and
completion of the HPV vaccine series.
Clinical Question(s)
The clinical question for this integrative review was formulated as follows: What is the
impact of the provider recommendation in relation to gaining a patient's acceptance of the HPV
vaccine and its subsequent initiation? Two broad project goals that served as the foundation for
the clinical questions included the following:
1) To determine if there is evidence supporting provider strategies to increase patient's
acceptance and initiation of the HPV vaccine.
2) To investigate best practices providers can employ to gain patient's compliance and
completion of the HPV vaccine series.
Inclusion and Exclusion Criteria
The studies considered included articles written in English, and published between 2011
and 2021, that included children and young adults aged 9-26 years. Criteria assessed through an
initial search of articles included articles were full-text, evidence-based, peer-reviewed, clinical,
and had national guideline recommendations. Additional inclusion criteria were articles that
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presented information about increasing HPV vaccination rates, barriers to HPV vaccine uptake,
and provider’ interventions that increased HPV vaccination rates.
Exclusion criteria were articles that were written in any languages other than English,
articles dated before 2011, and articles about ethnic subgroups. Additionally, unpublished
manuscripts, letters to the editor, short articles, abstract-only articles, uncompleted clinical trials,
podium speeches, articles that did not address the specific issue of education, and articles that
had not gone through the peer-review process were excluded. According to Whittemore and
Knafl (2005), researchers should allow for the simultaneous inclusion of experimental and nonexperimental research for integrative reviews to fully understand a phenomenon of concern.
Conceptual Framework
This integrative review utilized Whittemore and Knafl's methodology (2005) as a guiding
framework to provide organization and structure to the information gathered and presented on
strategies used by providers to gain a patient's acceptance of the HPV vaccine and its subsequent
initiation. This type of methodology allowed for a wide array of research evidence to be
examined and explored about HPV vaccination increase among young adults. Whittemore and
Knafl's (2005) strategies to enhance rigor in integrative reviews were applied to this review and
comprised the following five concepts: problem identification stage, literature search stage, data
evaluation stage, data analysis stage, and presentation. This method yielded a robust, unbiased,
and comprehensive review of the vaccine provider's impact in gaining patient’ acceptance of the
HPV vaccine and its initiation.
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Section Two: Literature Review
Information Sources and Search Criteria
Whittemore and Knafl's (2005) problem identification stage was utilized in the
comprehensive search for supporting literature relevant to the integrative review. This process
was used to capture as much literature as possible about increasing HPV vaccination rates among
adolescents and young adults. Multiple search strategies and various electronic databases were
used to conduct a broad literature search for relevant peer-reviewed articles. This broad search
spectrum allowed for minimal bias and a comprehensive rigorous review.
Whittemore and Knafl (2005) have stated that “well defined literature search strategies
are critical for enhancing the rigor of any type of review” (p. 548). A comprehensive literature
review was conducted to evaluate the strategies that most effectively improve HPV vaccination
rates among adolescents and young adults aged 9-26 years; this search was conducted by using
three databases: MEDLINE, the Cumulative Index of Nursing and Allied Literature (CINAHL),
and PubMed from Liberty University's Jerry Falwell Library. Additionally, a librarian located at
the practicum site, Eisenhower Medical Center, was consulted to identify valuable sources and
databases to facilitate a more comprehensive literature search, avoid bias, and capture relevant
data on HPV vaccinations.
CINAHL was the primary database used for the initial literature search to allow for a
comprehensive resource that covered a wide range of health topics, from nursing to multiple
allied health disciplines. The initial search focused on the clinical question of: determining if
whether or not there is evidence supporting provider strategies to increase patient’ acceptance
and initiation of the HPV vaccine.
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The CDC website was used for current statistical data on HPV infections, vaccination
rates, and HPV vaccination guidelines. Multiple keywords and keyword combinations were
employed in the search process to identify pertinent and current literature related to the topic.
The keywords utilized in the search process included: “human papillomavirus”, “HPV”, “HPV
vaccine”, “vaccinations”, “health education”, “HPV knowledge”, “healthcare provider”,
“barriers”, and “interventions”. Additional search terms were used to improve the results and
included “HPV vaccination”, “provider recommendation”, “education strategies”, “adolescents”,
and “HPV-related cancers”. A vast amount of relevant information was found regarding
improving HPV infection rates, vaccination rates, and vaccination guidelines among the
highlighted demographic.
A preliminary keyword search of the databases identified 578 articles. After exclusion
criteria were applied, 85 abstracts were screened, and 37 articles were kept for inclusion in the
integrative review. These articles were selected based on the review question that sought to find
information on strategies to improve HPV vaccination rates among adolescents and young adults
aged 9-26 years.
Quality Appraisal
Identifying the strength and quality of relevant evidence is necessary to decide on
healthcare practice changes. According to Whittemore and Knafl (2005), there is “no gold
standard for evaluating and interpreting quality in research reviews” (p. 550). Melnyk’s levels of
evidence model was used to appraise the literature for quality, content, and evidence strength
(Melnyk & Fineout-Overholt, 2015). A single reviewer examined the quality of each study. A
variety of levels of evidence existed among the articles included in this integrative review. Using
Melnyk and Fineout-Overholt’s (2015) criteria, a literature matrix was developed, focused on the
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article citation, level of evidence present, sample or setting for the study, the data collection and
interventions, key findings, limitations, and a summary of the findings. The literature chosen
included cross-sectional design studies, randomized controlled trials, non-randomized control
trials, systematic reviews, and cohort study designs. The remaining articles varied from level of
evidence I-VI, including quasi-experimental and randomized control trials. The complete matrix
and a comprehensive breakdown of each study are included in Appendix B.
In addition to the level of evidence matrix, the quality of the article guidelines was
examined and appraised according to the Appraisal of Guidelines Research and Evaluation II
tool (Brouwers et al., 2013). The systematic reviews and other clinical trials were appraised
according to the Scottish Intercollegiate Guidelines Network ([SIGN], 2019).
To increase transparency in the article review, Whittemore and Knafl’s (2005) method
and the preferred reporting items for systematic reviews and meta-analysis (PRISMA) model
were utilized to guide the literature search and appraisal process. These models facilitated a
structured search process and selection of relevant scholarly literature, aggregate results, and
discussion of the main findings. PRISMA is an evidence-based minimum set of items aimed at
helping authors to report a wide array of systematic reviews and meta-analyses that assess the
benefits and harms of a health care intervention (Moher et al., 2015). PRISMA focuses on how
authors can ensure a transparent and complete reporting of this type of research and facilitate a
comprehensive literature identification and screening process. The PRISMA flow chart can be
found in Appendix A.
Synthesis of Literature
Low HPV vaccinations among young adults were identified as the problem for this
integrative review. The purpose of the integrative review was identified along with definite
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concepts and variables previously outlined to include both conceptual and operational
definitions. Whittemore and Knafl (2005) have emphasized that a well-specified problem and
purpose in an integrative review "will facilitate the ability to accurately operationalize variables
and thus extract appropriate data from primary sources" (p. 548).
The literature was extensively searched using the electronic databases CINAHL,
PubMed’s, MEDLINE, and the Cochrane Library with various exploratory combinations of
keywords related to HPV vaccination statistics. "Well-defined literature search strategies are
critical for enhancing the rigor of any type of review" (Whittemore & Knafl, 2005, p. 548).
In addition to Whittemore and Knafl (2005), each manuscript was assigned a level of
evidence using Melnyk’s levels of evidence model-based on the study’s design, validity, and
applicability to the problem statement and purpose of this integrative review (Melnyk & FineoutOverholt, 2015). The matrix contained the citation, level of evidence, sample or setting for the
study, the data collection process and interventions, key findings, limitations, and a summary of
the findings. To increase transparency in the review synthesis, the PRISMA framework was
utilized to guide the literature search and appraisal process.
The literature review results clearly demonstrated the impact that providers have on
patient education, acceptance of the HPV vaccine, and initiation of the HPV vaccine series. In
addition, providers and their office staff have a role in patient compliance with the completion of
the required number of doses of the vaccine. These important concepts are discussed further in
the integrative review section of this report.
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Section Three: Results
Themes of Individual Studies
The three themes that emerged from the literature review were HPV vaccine hindrance,
educational strategies, and compliance strategies. These themes were consistent throughout the
reviewed articles. Providers have had a significant role in dispelling inaccuracies about the HPV
vaccine and educating patients on the benefits and low risk of the vaccine. Lastly, providers and
their staff have had a responsibility to ensure that patients complete the vaccine series and thus
become protected from the harmful effects of HPV.
HPV Vaccination Hindrance
Research studies on HPV vaccination have identified a lack of knowledge about HPV
and HPV vaccination as a source of nonadherence. Myths and opinions of HPV vaccination are
formed, and young adults cannot fully understand the importance of immunization and the
ramifications of not vaccinating. The knowledge of providers, adolescent parents, and young
adult’s knowledge about the importance of the HPV vaccine is imperative to the success of HPV
vaccination campaigns. These campaigns can contribute to increased vaccination rates among
adolescents and young adults.
In Piedimonte et al.’s (2018) study, researchers determined that the level of knowledge
and awareness of HPV and cervical cancer among university students was a modifiable risk
factor to increase HPV vaccinations. The study sought to develop a targeted education and
vaccination campaign to increase uptake, hypothesizing that an "HPV education initiative can
increase awareness and thus lead to increased vaccination uptake" (p. 441).
Barriers and Attitude. HPV vaccinations have been low despite evidence of the high
efficacy of the HPV vaccine. "Since FDA approval of the first HPV vaccine in 2006, overall
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coverage of the target age group remains low" (Manhart, 2011, p. 5238). Low vaccination rates
suggest that identifying attitudes and barriers towards vaccination and increasing vaccine uptake
are necessary. The literature results have identified that barriers such as relationship status,
sexual activity, cost, HPV education, parents’ versus healthcare providers' recommendation, and
vaccine adverse effects were crucial influences of whether or not an individual decided to accept
vaccination.
Wilson et al. (2016) assessed attitudinal factors associated with initiation and completion
of the HPV vaccination. Main attitudes identified from the study on vaccination uptake included
HPV and vaccine knowledge, reproductive health, and future HPV vaccine use. Although the
HPV vaccine has been available in the US for over 13 years, only “one-third of adolescents have
been fully immunized with all three recommended doses, and only one-third of women ages 9-26
have received one dose of the three-dose series” (Wilson et al., 2016, p. 6). The study identified
that cost along with the novelty of the HPV vaccine and being in a monogamous relationship
were key barriers to vaccination. Additionally, the study findings confirmed that primary care
providers’(PCPs) consistently recommending the HPV vaccine to adolescents and young adults
is vital to vaccination. Conclusions identified the need for further discussion of sexual risk
assessment and how relationship and sexual activity play a vital role in acquiring HPV and the
hesitance towards vaccination.
Public health departments across the US have benefitted from the robust studies on
barriers to HPV vaccination initiation and completion. Understanding the barriers and finding
ways to combat these barriers and attitudes has been vital to increasing HPV vaccination rates. In
a study by Oldach and Katz (2012), researchers identified various barriers that hindered HPV
vaccination among male and female adolescents in the Ohio Appalachia area. The participants
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identified concerns such as potential vaccine side effects, parental’s perceptions that their
children were not sexually active, and lack of knowledge about the vaccine. With this study’s
results, the researchers concluded that, globally, health departments needed to identify future
educational tools and interventions to increase HPV vaccinations among this population,
focusing on promoting different informational needs for parents of males versus parents of
females to make informed decisions about the HPV-vaccine for their children, since the
perception of sexual activity and relationships varied among these groups.
Relationship or Sexual Activity Status. Researchers have correlated relationship and
sexual engagement statuses as significant barriers to vaccination. Data have identified that
relationship and sexual activity status among young adults’ impact decisions on whether or not
they choose to be vaccinated. Thompson, Vamos, Sappenfield et al. (2016) conducted a study on
how relationship status impacts primary reasons for interest in the HPV vaccine among young
adult women aged 18-26. They performed a survey-weighted logistic regression analysis and
concluded that "married women were more than 40% less likely to be interested in HPV
vaccination compared to never-married women and women living with a partner" (Thompson,
Vamos, Sappenfield et al., 2016, p. 3122). These results highlight the importance of how
relationship status in young adults impacts HPV vaccine interest.
The study conducted by Thompson, Vamos, Sappenfield et al. (2016), participants ages
19-26, believed they did not need the HPV vaccine because they were either married or in a
monogamous relationship. The participants acknowledged their belief that being in a
monogamous relationship or married lessened their risk for HPV and that they, therefore, did not
need to become vaccinated. This belief hindered this population from being appropriately
vaccinated against HPV. Robust research exists on acquiring HPV, and the “lifetime risk for
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acquiring HPV for a woman with only one sexual partner is 85%” (Thompson, Vamos,
Sappenfield et al., 2016, p. 3123). The researchers emphasized the need for additional qualitative
research to explore how relationships status impacts HPV vaccination decisions.
Another study conducted by Thompson, Vamos, Vazquez-Otero et al. (2016), highlighted
the importance of vaccinating college students due to their increased risk for HPV infection.
Additionally, the researchers analyzed how relationship status impacted decision-making
regarding the HPV vaccine. The researchers found that among the surveyed college students,
HPV vaccination rates increased for all relationship status groups and marital status groups for
males and females. They concluded that “higher increases were found among women either
living with a partner or married than other relationship status or martial groups” (Thompson,
Vamos, Vazquez-Otero et al., 2016, p. 94). This study opened the dialogue for public health
efforts that targets college students and explores HPV vaccination programs among them.
Research has shown strong evidence that misconceptions about relationship and sexual
status have a significant impact on the initiation and completion of the HPV vaccination series.
In a cohort study done by Smith et al. (2015), their research results yielded strong evidence that
HPV vaccination did not significantly affect clinical indicators of risky sexual behavior among
adolescent females. These findings suggest that “fears of increased risky sexual behavior
following HPV vaccination are unwarranted and should not be a barrier to vaccinating at a young
age” (Smith et al., 2015, p. E79). Bednarczyk et al. (2012) conducted a retrospective cohort
study among adolescent girls aged 11-12 years. They concluded that HPV vaccination at the
recommended ages was not associated with increased sexual-activity-related outcomes. During
the research for this integrative review, this was the only study to evaluate sexual activity in
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relation to HPV vaccination, emphasizing that further research is needed to address this barrier
equating increased sexual activity with vaccination.
A study conducted by Cummings et al. (2012) examined the impact of HPV vaccination
on subsequent HPV detection and sexual behaviors among urban adolescents in a clinical setting.
Women that were selected for the study completed a questionnaire and face-to-face interviews to
assess sexual behaviors. Both sexually active and non-sexually active adolescents were sampled.
Participants disclosed their sexual behaviors for the one-year period prior to the study, and a
face-to-face interview was conducted to assess sexual behaviors within the last two months of
the study. The study results demonstrated that HPV vaccination was associated with fewer
vaccine-type HPV infections despite incomplete vaccination and high-risk sexual behaviors. This
data suggest that the vaccine did not alter sexual behaviors and that the only behavioral
difference found was, that recruited women used condoms more frequently.
Vaccine Cost, Safety, and Efficacy. STI, including HPV infections, impose a
considerable medical cost on the healthcare system. Chesson et al. (2021) estimated that eight
billion dollars would be spent on combating HPV-virus-related health disparities annually.
Therefore, prevention and support of vaccine uptake will be vital to combating astronomical
treatment costs of HPV-related illnesses in the future. With this estimated cost, vaccination
initiatives, provider engagement, and parental support are crucial to decreasing the healthcare
cost of HPV-related health disparities through vaccination initiation and completion. The cost of
vaccinating to prevent HPV-related disparities is worth the cost of treatment for these disparities.
As with any other vaccinations, the cost can hinder vaccination uptake, particularly when
a vaccine is not mandatory. Research studies have identified that the cost of vaccination uptake
outweighs the treatment cost of HPV infections that cause cancer in the young adult population.
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In a randomized study conducted by Patel et al. (2012), 41.3% of the participants indicated that
the most common reason they had for not intending to undergo HPV vaccination was the high
out-of-pocket costs or insurance co-payments. Piedimonte et al. (2018) identified students
vaccinated during the pilot vaccination campaign; 50% did not complete the three-dose
vaccination schedule due to financial reasons and a lack of insurance coverage. To combat this
reason for not being vaccinated, many states have developed vaccination programs to assist
healthcare facilities and health departments in acquiring the vaccine at low or zero cost to
patients.
Pearson et al. (2014) conducted a study using the Burden of Disease Epidemiology,
Equity, and Cost-Effectiveness program to find ways to reduce the overall cost per vaccinated
individual. The "average cost of the HPV vaccine in the US is $101-135 per dose and $61
administration cost per dose" (Pearson et al., 2014, p. 62). This cost-effectiveness analysis
compared the cost of two-dose versus three-dose HPV vaccination. Additionally, the researchers
discussed key strategies to lowering HPV vaccine costs when healthcare practices buy HPV
vaccines in bulk versus doses. The study suggested that government agencies negotiate vaccine
prices with suppliers for large-scale public programs to offset the cost of the HPV vaccine.
Another critical determinant of the cost-effectiveness is reducing the HPV vaccine to being two
instead of three doses if the efficacy of two doses is similar to that of three doses. However, this
suggestion would need to be further examined by scientists to test the effectiveness of a two-dose
vaccination regardless of a client's age.
Wilson et al. (2016) identified how the Vaccines for Children (VFC) program and
Vaccine Patient Assistance programs are valuable to communities worldwide that assist in the no
cost or low cost of the HPV vaccine immunization. The VFC program and the Merck Vaccine
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Patient Assistance Program help with the cost of vaccinations. The VFC offers the HPV vaccine
free or at low cost for girls aged 9-18 years. For women of 19-26 years of age who do not have
insurance or have insurance that does not pay for the vaccine, the Merck Vaccine Patient
Assistance program can provide the vaccine free of charge or at a low cost (Merck, 2014).
Vaccine safety and efficacy should additionally be discussed to improve HPV vaccination rates
among the targeted population. Currently, only the Gardasil 9 HPV vaccine is available in the
US to prevent HPV and related infections. Gardasil 9 protects against HPV types 6, 11, 16, and
18, the most common HPV types responsible for HPV-associated cancers, including cancers of
the cervix, vulva, vagina, penis, anus, and oropharynx. Completing the HPV vaccine series is
recommended for both females and males before the first sexual encounter. "Half of all new
infections are diagnosed in girls and young women between 15 and 24 years of age, so early
vaccination is important" (CDC, 2020).
The HPV vaccine Gardasil, a quadrivalent HPV4 vaccine, has been shown to be nearly
100% protective against strains 6, 11, 16, and 18. This vaccine covers the most high-risk strains
of HPV, which can cause cervical cancer and genital warts. The efficiency rate is greater than
99% after a series of three doses with antibody responses greater for females 9 to 15 years as
compared with those older than 15 years of age" (Burns et al., 2013, p. 437). Gardasil 9,
additionally known as Nonavalent, became available in 2014 to prevent HPV strain types 6, 11,
16, and 18 and five additional oncogenic type strains, strains 31, 33, 45, 52, and 58. The
"oncogenic HPV types covered by Gardasil 9 are detected in about 80% of all cervical cancers"
(Petrosky et al., 2015). This vaccine is given as a shot intramuscular and requires three doses at
zero, two, and six months.
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Huh et al. (2017), in a primary analysis of young women aged 16–26 years, showed the
efficacy of the Gardasil 9 HPV vaccine against infections and disease related to HPV 31, 33, 45,
52, and 58, as well as non-inferior HPV 6, 11, 16, and 18 antibody responses when compared
with Gardasil HPV vaccine against infections and disease related to HPV 6, 11, 16, and 18. The
study findings noted that between September 2007 and December 2009, researchers recruited
and randomly assigned 14,215 participants to receive the Gardasil 9 (n = 7,106). In the perprotocol population, the incidence of high-grade cervical, vulvar, and vaginal disease related to
HPV 31, 33, 45, 52, and 58 represented 97.4% efficacy. HPV strains 6, 11, 16, and 18 were noninferior in the Gardasil 9 vaccine versus the Gardasil vaccine group from month one to three
years after vaccination. No clinically meaningful differences in serious adverse events were
noted between the study groups. Eleven participants died during the study follow-up period;
none of the deaths were considered vaccine-related. Vaccine efficacy was sustained for up to six
years. The Gardasil 9 vaccine could provide broader coverage and prevent 90% of cervical
cancer cases worldwide (Cheng et al., 2020).
An abundance of research in the literature has indicated that the HPV vaccine is effective,
safe, and well-tolerated, with low side effects. No greater adverse events occurred with the HPV
vaccines compared to any other vaccine for this age group. In Markowitz et al.’s (2014) report,
the authors concluded that there was no difference between the HPV vaccine and its control
groups regarding serious adverse events, new onset of chronic diseases, autoimmune disorders,
and death. The most common general symptoms included a headache, nausea, and fever.
Contraindications included pregnancy and severe allergic reactions after the first dose.
Manufacturers suggest that persons with a history of immediate hypersensitivity to yeast should
not receive the quadrivalent vaccine (Gardasil and Gardasil 9). Additionally, prefilled syringes of
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the bivalent vaccine (Cervarix) are contraindicated for those with anaphylactic latex allergy. It is
recommended that providers use the single-dose vials of the bivalent vaccine because it contains
no latex (Markowitz et al., 2014).
Parents and Healthcare Provider Recommendations. Current literature has identified
that the single most effective predictor for adolescent vaccine uptake is a strong recommendation
by the healthcare provider. “Improving healthcare providers’ communication is among the most
important strategy for increasing HPV vaccine uptake in the US.” (Gilkey et al., 2015, p. 181). In
one study, barriers and attitudes toward HPV vaccination were studied among urban, minority,
and economically disadvantaged youth. According to the authors of this article, "our work
indicates a profound lack of awareness about HPV vaccination as well as the important influence
of parents among urban, economically disadvantaged youth" (Miller et al., 2014, p. 839).
According to the CDC (2021), youth below the poverty line have a lower vaccination rate than
youth above the poverty line. The study emphasizes the importance of providers educating
adolescents and their guardian(s) about HPV and the potential risks regardless of the patient’s
socioeconomic status.
Alexander et al. (2015) conducted a 20–30-minute interview among PCPs about their
knowledge, attitudes, and practices regarding male HPV vaccinations. Although providers
viewed the HPV vaccine as safe and effective, they were uncomfortable discussing vaccination
with parents of adolescent males. The provider’s lack of knowledge was the significant factor for
their hesitation in promoting the vaccine among this group. While several of the providers
believed that both males, and females should be vaccinated, several did not see the importance of
male patients receiving the vaccine. Many were not knowledgeable about the HPV vaccine, and
their recommendations aligned with the ACIP. This study concluded that there needed to be
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“further research on effective interventions to increase physician knowledge about cancerprevented indications for the HPV vaccination” (Alexander et al., 2015, p. 4086).
Research has shown that healthcare providers’ lack of knowledge and perceived barriers
regarding HPV and HPV vaccination account for the variation in vaccine delivery and
completion. Rutten et al. (2017) conducted a study that tested the hypothesis that healthcare
provider’s knowledge, barriers, and perceived parental barriers regarding the HPV vaccination
caused low HPV vaccination rates. This study evaluated clinician knowledge about HPV and
HPV vaccination along with barriers that hindered the delivery of the HPV vaccine in a clinical
setting. The study’s conclusion supported the hypothesis that greater clinical knowledge is
associated with high rates of HPV vaccination initiation and completion, while clinician barriers
and perceived parental barriers are associated with lower vaccination rates.
A lack of research exists on how PCPs perceive HPV vaccine guidelines. Perceived HPV
guidelines can undoubtedly hinder the initiation and completion of the HPV vaccine series. A
provider’s robust knowledge and understanding of the vaccine guidelines are essential to an HPV
vaccination campaign. Kulczycki et al. (2016) highlighted the importance of more vigorous
efforts to improve HPV vaccination rates among PCPs caring for 11–12-year-old girls in their
care. Vaccinations with the HPV vaccine were advised before exposure to HPV, which was more
likely during adolescence. PCPs used that age window to promote vaccination to decrease the
future cost of HPV-related illness. This study highlighted how it is imperative that PCPs
incorporate critical aspects of HPV vaccination guidelines in their care routines. The study found
that only “67% of their sample indicated they were likely to prescribe the vaccine to girls might
be attributed to the fact that 34% of PCPs reported some ambivalence about the clarity of
professional guidelines” (Kulczycki et al., 2016, p. 36). Providers working with this population
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must be knowledgeable and adhere to HPV vaccination guidelines. With a lack of clarity of
HPV, PCPs may continue not incorporating HPV vaccine practices in their clinics.
A provider’s recommendation is significant and necessary for increasing HPV
vaccination rates. Mohammed et al. (2016) reported that 72.65% of girls and 51.8% of boys
received HPV vaccination recommendations from their PCPs, which varied among several
sociodemographic characteristics. This study highlights the importance of PCPs recommending
the vaccination at the same rate for girls and boys. The vaccine was recommended to girls 2.57
times more than to boys in this study. With the numerous disparities in provider recommendation
of the HPV vaccine, this study highlights the importance of PCPs intervening at the provider
level to facilitate increased knowledge and promotion of the HPV vaccine in the adolescent and
young adult population. Robust evidence exists that PCP support and recommendations on HPV
vaccination are necessary to increase HPV vaccinations in young adults, however, a parent’s
knowledge about HPV, the vaccine, and related risks is equally important to increase vaccination
(Mohammed et al., 2016).
In a study completed by Mullins et al. (2013), "parents were the second most preferred
source of information for girls. For parents to provide accurate information, parents themselves
need education about the vaccine" (Mullins et al., 2013, p. 4897). As shown by these results, the
PCP must educate the guardian in full, which leads to increased vaccination rates. "Effective
educational interventions targeting parents may lead to improved vaccine knowledge among
girls, as well as increased acceptance of the vaccine among parents" (Mullins et al., 2013, p.
4899). Discussing the vaccine with the adolescent and guardian before the age of 11 can increase
awareness of HPV infections and the vaccine and inform the adolescent and guardian of
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upcoming preventive anticipatory measures. Educating both parties increases their comfort level
with the subject manner and makes discussing HPV infection productive and beneficial.
Study results from Bhatta and Phillips (2015) determined that one out of five parents had
discussed the HPV vaccine with their children and their children’s PCPs. Additionally, only
19.4% of children and adolescents reported discussing the HPV vaccine with their parents. This
low rate was equated to a “general lack of awareness and knowledge about HPV, HPV vaccine,
HPV-related diseases, and the risk associated with not vaccinating adolescents” (p. 73). Other
reasons included a lack of knowledge about the safety and efficacy of the vaccine, cultural
attitudes and beliefs regarding sexual behaviors, and prevention strategies. With this evidence,
there is a need to improve and increase community knowledge about the HPV vaccine and the
effectiveness of vaccination in preventing HPV-related cancers. Indicated by this study, there
need to be more public health education resources available to parents to assist them in
discussions on HPV and the HPV vaccine with their children to improve awareness and
knowledge about HPV infection and prevention strategies.
Healthcare providers must examine parent’s vaccination decision-making processes to
identify strategies to increase vaccination uptake during clinic visits. Getrich et al. (2014)
conducted a mixed-method study examining HPV vaccine decision-making among female
adolescent’s mothers utilizing a structured questionnaire and semi-structured interviews. The
study concluded that identified factors such as education, socioeconomic status, and health care
access among the mothers played a pivotal role in their decision to vaccinate their daughters.
Parents’ health literacy levels were a key factor in their limited knowledge about HPV and the
HPV vaccine. Numerous mothers were uncertain about their daughters’ vaccination statuses and
perceived a high sense of sexual risk equated with the HPV vaccination; thus they were hesitant
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about vaccination. Given this data, PCPs need to “identify and utilize innovative approaches to
optimize vaccine use” (Getrich et al., 2014, p. 62). This study highlights how influential the
PCPs recommendations are and the importance of identifying specific informational needs about
HPV infection and the HPV vaccine, as well as communication strategies for parents to allow for
improved decision-making regarding their children’s health. Participants in the study reported
that the “reason they did not get the vaccine or subsequent doses was simply that the clinician
had not raised the topic” (Getrich et al., 2014, p. 56). Based on the findings from the study, there
needs to be further research that contributes to the literature on decision-making processes for
parents regarding HPV vaccinations for their children.
Educational Strategies
Although there has been strong evidence-based research on the effectiveness of the HPV
vaccine at preventing anogenital cancer, only “70% of adolescent females and 66% of males in
the US have initiated the series” (Walker et al., 2019). Educational strategies for clinicians,
parents, adolescents, and young adults can be instrumental in improving the strength and
consistency of recommendations to increase HPV vaccinations. Piedimonte et al. (2018) have
suggested that educational tools such as educational booths, pamphlets, emails, social media
infomercials, and face-to-face presentations be used among college students to increase HPV
knowledge and facilitate on-site vaccination or appointments through student health centers.
During the first phase of the study, where participates were given informative pamphlets, 50% of
the 56 participants completed the three-dose regimen. During the second phase, where the
researchers extended their platform to social media and emailed infomercial sessions, 64 out of
151 participants initiated their first dose.
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Tools such as video presentations and informational pamphlets can be provided to young
adults to help assess their intent to vaccinate and increase their knowledge base regarding HPV
infection and the vaccination series. These educational tools can present the risks of not being
vaccinated, such as developing different types of HPV-associated health disparities like cervical
and oropharyngeal cancers. Fu et al. (2014) conducted a systematic review of 33 studies of HPV
vaccination educational interventions that hypothesized that “HPV vaccination may be more
readily influenced by educational intervention” (p. 1907). A majority of the studies in this
systematic review found significant improvement in the attitude and decision-making of
adolescents and young adults regardless of the content and format of the educational
intervention.
Educational Videos and Presentation Sessions. Vanderpool et al. (2013) conducted a
study to test the efficacy of a DVD intervention that promoted HPV vaccine series completion.
The researchers compared completion rates of the three dose HPV vaccination series among
young women who received the first dose from study personnel at the beginning of the study
after reviewing an HPV educational session via a DVD format. In this study, the difference
between the intervention and control conditions was either viewing a 13-minute video about
HPV or not. Both groups of participant’s received a CDC-produced HPV vaccine fact sheet and
a t-shirt. The authors reported that 11% more participants in the intervention versus the control
group received all three doses of HPV vaccine within nine months as assessed via medical record
review. Furthermore, women who viewed the DVD educational model versus nonviewers were
“2.44 more likely to complete the series” (Vanderpool et al., 2013, p. 95). The study results
concluded that this type of theory-grounded DVD intervention educational format has a high
potential to increase vaccination rates among young women.
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Groom et al. (2017) conducted a study to determine if a system-wide assessment and
feedback communication tool for healthcare providers would increase HPV vaccination initiation
rates in nine primary care facilities within the Kaiser Permanente healthcare system located in
Florida. The content of the communication tool was adapted from the CDC-developed
presentation, “You Are the Key to Cancer Prevention” (CDC, 2019b). The CDC is aware that
HPV vaccination goals are not being met, and robust research has determined that adherence to
the full three dose regimen is related to the lack of knowledge and promotion of vaccination by
healthcare providers. The CDC website provides access to a vast amount of educational
information on HPV for healthcare providers. Healthcare providers include physicians, nurses,
nurse practitioners, pharmacists, physician assistants, and medical students, that can use the
information found on the website to assist in making effective recommendations and answering
parents’ questions.
Within the study conducted by Groom et al. (2017), the researchers developed a two-part
informational tool that discussed topics regarding coverage rates for vaccines recommended for
adolescents, including HPV initiation and series completion. Communication themes of the
informational tool “stressed the importance of making strong recommendations for HPV
vaccination, highlighting its role in cancer prevention, explaining the need for the vaccine to be
given and including personal statements of support for vaccination” (Groom et al., 2017, p. 590).
Additional information included up-to-date information on HPV infections and disease, the HPV
vaccine, and ways to communicate successfully with parents about HPV vaccination.
Pamphlets or Brochures. Krawczyk et al. (2012) compared the efficacy of two HPV
educational interventions on increasing HPV knowledge and vaccination intentions in college
students. Male and female undergraduate participants were recruited from a university in
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Montreal, Quebec, Canada. Using theory-based interventions, the participants were randomly
assigned to either a written HPV pamphlet, an HPV video, or a control group. HPV knowledge
and vaccination intentions were assessed pre-intervention and post-intervention. Low baseline
knowledge and intentions were found across groups. Post-intervention, participants in the written
and video interventions had significantly higher knowledge and intentions than the control
group. No differences were found between written and video interventions on knowledge or
intentions. This study comparing HPV educational formats suggests that both written and video
interventions are equally effective in educating individuals about HPV and increasing young
adults' vaccination intentions. Modern robust technology application options make it possible to
provide healthcare providers with various technology options to help young adults decide
whether or not to vaccinate against HPV.
Cassidy et al. (2014) conducted a quality improvement project to “determine if an
evidence-based educational brochure and reminder system can increase HPV vaccine uptake and
dose completion rates” (p. 155). The brochures used in the study were developed based on
predictors of parental’s acceptance and the health belief model (HBM) concept, a “theoretical
framework concluding that vaccine acceptability was higher when parents believed that the
vaccine was effective, when the vaccine was recommended by providers, and when perceived
susceptibility to contracting HPV infection was likely” (Cassidy et al., 2014, p. 157). The
educational frequently asked questions (FAQ) brochure consisted of FAQ about HPV, FAQ
answers, evidence-based discussion, and the HBM construct the educational brochure met.
Parents and children were given educational brochures at the time of their clinic visit for
preventive care. The results showed that the educational FAQ brochures significantly improved

ACCEPTANCE AND INITIATION OF THE HPV VACCINE

32

HPV vaccine and dose completion. Future implications for this evidence-based project signifies
the importance of focusing on effective educational and reminder approaches.
Interactive Apps and Active Learning Modules. Working with third-year pediatric
residents, Real et al. (2021), conducted a usability evaluation of a novel smartphone application
for the HPV vaccination. The researchers sought to report communication strategies to promote
effective HPV recommendations among clinicians. “The HPV vaccine: same way, same day
smartphone application is a novel health communication intervention allowing clinicians to
deliberately practice evidence-based vaccine recommendation strategies” (Real et al., 2021, p.
742). Clinicians interviewed during the study acknowledged feeling ill-prepared to counsel
vaccine hesitancy with patients. This interactive web application allowed clinicians to actively
learn by engaging in role-playing scenarios featuring an animated parent avatar hesitant about
vaccine initiation (Real et al., 2021). The study identified that the interactive app enhanced
clinician's skills at administering evidence-based HPV vaccine communication strategies.
Additionally, this app offered support for future trials on this type of intervention to improve
clinician HPV knowledge. This provides another avenue to allow clinicians to enhance their
knowledge and confidence in articulating the benefits of the HPV vaccine among patients.
A substantial amount of research on this type of interactive learning has been used
globally in learning institutes to interactively improve adult learning. Learning-based
applications focused on increasing the willingness to vaccinate can be instrumental in helping
clinicians develop educational and communication strategies to promote vaccination.
“Educational initiatives aimed at current medical students may be an avenue to enhance provider
knowledge and thereby improve vaccination rates” (Wiley et al., 2019, p. 357). Researchers at a
medical school in Texas conducted a study on team-based learning modules in an undergraduate
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medical curriculum to teach medical students about HPV-related cancers and communication
strategies to increase willingness to vaccinate. These learning modules can equip medical
students with various communication skills that will enhance their knowledge of HPV, thus
preparing them to be confident in future medical practices when addressing HPV vaccinations
with their clients. The interactive application allowed medical students to watch interactive
clinical scenarios between patients and physicians that involved HPV vaccination. The medical
students were able to participate in the interactive models to identify weaknesses in their
knowledge of HPV and then hone in on those weaknesses by participating in detailed topics on
HPV to more comprehensively understand the topics. Based on the study’s results, there seems to
be promising data to support the use of active learning modules as an education strategy to
improve providers’ knowledge of HPV and confidence to discuss its relevance once they practice
medicine.
Patel et al. (2012) explain that “research should find ways to implement HPV
interventions via technologies acceptable among medical college students, to include text
messaging, e-mail, and social networking application, as it could improve the efficacy of
intervention” (p. 151). In a study conducted by Johnson-Mallard et al. (2019), the researchers,
hypothesized the feasibility of technology increasing informed decision-making among medical
students through the use of smartphones, and mobile health tracking apps. Evidence was
explored to support strategies to facilitate digital health technologies aimed at increasing risk
perception of the HPV virus and awareness of the HPV vaccine. The researchers developed a 54item electronic questionnaire that explored “digital health technologies in addition to HPV
knowledge, individual risk perception, and awareness of the HPV vaccine” (Johnson-Mallard et
al., 2019, p. 87). The support for digital technology platforms to disseminate evidence-based
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HPV data and HPV vaccination educational information among medical academics and other
settings can improve health care providers’ confidence in discussing topics related to HPV and
HPV vaccines, thus improving healthcare recommendations to vaccinate.
Compliance Strategies
The availability and supply of the HPV vaccine are abundant for adolescents due to the
VFC program, which assures universal vaccination coverage for minors. However, it has been
reported that difficulties in successful vaccine implementation beyond the first dose are due to a
lack of functional tracking systems and reminder capabilities (Getrich et al., 2014). Additionally,
current literature has indicated an “increase in the use of text messaging and interactive apps as
mobile health interventions, with evidence that these methods have succeeded in reducing
missed appointments, educating adolescents about sexual health, and tracking patient
information” (Johnson-Mallard et al., 2019, p. 85). Community Preventive Services Task Force,
an entity of the CDC, has endorsed an evidence-based strategy to increase vaccination rates by
sending various types of reminder messages to alert clients of vaccine recommendations as part
of their vaccination compliance initiative (Community Preventive Services Task Force, 2015).
Electronic Health Record Reminders. Various research studies have supported the use
of clinical reminders within a patient’s electronic health record (EHR). Bae et al. (2017) reported
promising data that physicians who use clinical reminders are more likely to order HPV
immunizations for their patients. Furthermore, given that HPV incidence significantly decreases,
with small increases in vaccination rates, clinical reminders serve as an instrumental compliance
strategy to increase HPV vaccination. “EHRs have the ability to provide clinical reminders that
support evidence-based care; as such, there is an expectation that such systems will improve care
processes and outcomes” (Bae et al., 2017, p. 353). Clinical research in vaccination uptake has
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shown that using EHRs as a clinical support tool improves preventive care services, such as
vaccinations, preventive medication prescriptions, screening, and preventive measures in the
healthcare setting. EHRs have the capability to employ clinical reminders that may facilitate an
increase in HPV vaccination rates. Conclusions from the study by Bae et al. (2017) identified
that “clinical reminders from EHRs are positively correlated with better care processes related to
HPV vaccination” (p. 56). Their data results identified that this was more prevalent in the male
population. Given that males have a higher prevalence of HPV infections, the data results are
essential in incorporating clinical reminders within EHRs to increase vaccination uptake.
Postcard Reminders. The CDC Community Guide currently sends reminder messages
to alert parents of vaccines recommended for their children. This postcard reminder strategy
targeting immunization, including HPV vaccine initiation, has shown a moderate increase in
vaccination uptake. Various research studies have supported the effectiveness of postcard
reminders, and, if used, other compliance strategies, in boosting vaccination uptake. Staras et al.
(2020) showed that postcard reminders increased HPV vaccine initiation of at least one dose by
60% for girls. The study assessed “the percentage increase in HPV vaccine initiation from
reminders increasing preventive care visits or increasing the likelihood of vaccine receipt during
preventive care” (Staras et al., 2020 p. 1). Guided by a health belief model, researchers
developed a postcard reminder intervention, “86% of parents in the Medicaid and CHIP enrollees
reported preferring to receive health information about their child by mail” (Staras et al., 2020, p.
3). The results from the study identified that postcards reminders along with providers’
recommendations at clinic visits increased HPV vaccinations by 44%. Only 8.9% of vaccination
were attributed solely to postcard reminders. Future implications for this data suggest that
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“decreasing the time between vaccine reminders and preventive care appointments may
maximize the priming effect of reminders” (Staras et al., 2020, p. 6).
Phone or Email and Text Message Reminders. Technology improvements have
facilitated many adolescents and young adults having unlimited text message capability through
their phone services. With the on-the-go mentality among these two populations, they prefer the
text message option to communicate vaccine reminders (Hofstetter et al., 2017). This
communication method has been effective in scheduling appointments and providing reminder of
appointments for vaccine initiation and completion. Hofstetter et al. (2017) conducted a study
that showed how text-message reminders, particularly those with embedded educational
information, benefitted general pediatric vaccination. This was a randomized clinical trial that
compared the effect of plain text versus educational text message reminders on receipt of the
HPV vaccination among four pediatric primary care clinics. Clients that were “sent plain rather
than educational text message reminders were more likely to receive the needed vaccine by
4weeks, but not 12 or 24weeks, after the initial message” (Hofstetter et al., 2017, p. 4554). The
results concluded that plain or educational text messages were beneficial in increasing HPV
vaccination rates. However, plain text messages reminders due to their simple and direct
message, were likely to be more beneficial in the short-term than the long-term.
Additional studies by Rand et al. (2017) and Reiter et al. (2012) have provided additional
support for email, EHR, phone, and text message reminders as crucial for increasing HPV
vaccination rates. Both studies identified that generated text messages reminders were beneficial
for clients with valid phone numbers and the capability to receive text messages. Current studies
in the literature have suggested that if the compliance strategies discussed are combined with
other complementary interventions, there is potential to increase HPV vaccination among the
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population identified. This is an effective strategy healthcare providers can use to promote HPV
vaccination among the adolescent and young adult populations (Francis et al., 2017).
Additionally, the CDC has a wealth of educational videos, tutorials, and informational tools
available to providers on the CDC website that can be utilized for one to become educated on
HPV, the HPV vaccine, and preventive measures. Since providers’ recommendations are pivotal
to vaccination initiation and completion, the CDC has developed five ways to boost HPV
vaccination rates for healthcare providers.
Implementing these practical and proven strategies within a provider’s healthcare setting
is necessary to increase vaccine uptake. Firstly, they recommend bundling required adolescent
vaccines in the same way on the same day to include the HPV vaccine. Secondly, providers need
to ensure their staff receive the same training on how to successfully communicate with clients
about HPV and the vaccine. Thirdly, providers should use all opportunities to vaccinate by
establishing clinic policies that check immunization at each visit, recommend vaccination at all
times, and establish automatic call reminders. Fourthly, providing personal examples of how
providers support the HPV vaccine for their family members will make the client more
comfortable in receiving vaccinations. Lastly, providers and their staff should learn how to
accurately answer vaccination questions using language clients can fully understand.
Synthesis of Results
Toronto and Remington (2020) emphasize that data analysis of an integrative review
"requires the reviewer to order, code, and categorize data from multiple sources that may have
used diverse methodological perspectives" (p. 60). This integrative review section of the data
analysis reveals a comprehensive interpretation of the data extracted from the research articles,
appraised for relevancy. A thorough and unbiased understanding of research articles and an
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innovative synthesis of the evidence were used to summarize the research articles to support the
integrative review purpose (Whittemore & Knafl, 2005). Further in-depth data analysis,
including data reduction, data display, data comparison, and conclusion drawing and verification,
were utilized in the literature review.
The primary focus of this integrative review was education promotion among healthcare
providers to increase HPV knowledge, initiate the HPV vaccine, and ensure completion of the
vaccine series. Having completed a detailed examination of the literature, the project leader
found significant evidence to support three broad themes. The themes are HPV vaccination
hindrance, HPV educational strategies, and HPV vaccine compliance strategies for completion of
the vaccine series.
The research articles examined during the integrative review recognized the lack of HPV
knowledge among providers and staff, parents, and patients. This lack of knowledge among all
persons created barriers and negative attitudes, which hampered vaccination uptake among
adolescents and young adults. Parents were particularly concerned about HPV vaccine uptake
and sexual activity in their adolescents. Individuals who were not sexually active or in an
exclusively monogamous sexual relationship were less likely to feel the need to initiate HPV
vaccination. Vaccine cost was an issue in many earlier studies, but with time, there have been
many programs to make the vaccine free or at minimal cost to patients. Literature supporting
educational strategies and vaccine safety has concluded that the HPV vaccines are effective, safe,
and strongly recommended starting at age 9 up to 26. When healthcare providers recommended
the vaccine, patients and their parents were more likely to initiate the vaccine series.
Conducting an up-to-date literature review identified methods to educate adolescents and
young adults about HPV infection and strategies to improve HPV vaccination rates. The
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literature review distinguished educational issues from personal preferences and characterized
evidence in a helpful and recognizable manner to further influence adolescents and young adult's
knowledge and outcomes with HPV prevention. Examples of effective educational strategies
include video, pamphlets, brochures, and interactive apps.
Throughout the literature review, many compliance strategies were offered as ways to
increase the completion of the vaccine series, whether it was the two-dose or the three-dose
series. Examples of the strategies offered were postcard reminders, phone messages, email, and
text messages. Many of these strategies were used in combination with another strategy to
increase the effectiveness of compliance.
The three themes discussed of HPV vaccination hindrance, educational strategies, and
compliance strategies for completing the vaccine series have been comprehensively covered in
the literature and are completely effective if utilized by providers and their staff. Unfortunately,
despite the efforts by the CDC and researchers to study and produce educational materials and
compliance strategies that work, the overall rates of HPV vaccination remain relatively low in
comparison to other childhood and young adult vaccines.
Ethical Considerations
Identifying strategies to improve HPV education among young adults did not raise any
ethical concerns. An application was submitted to the Liberty University Institutional Review
Board. It was found to be in accordance with the Office for Human Research Protections and
Food and Drug Administration regulations and not classed as human subjects research (See
Appendix C). Mandatory training was completed through the Collaborative Institutional Training
Institution on basic biosafety; a completion certificate was provided (See Appendix D).
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Timeline
1. Pre-Proposal approval submit in Fall of 2017 to DNP Proposal Committee for
approval
2. Scholarly Project Chair assigned Fall of 2017
3. Project Site Letter of Support and Preceptor Summer 2018
4. Phase 1 components completion in Fall 2018
a. Project proposal section 1 and 2 submitted in NURS 840
b. Project proposal section 1-3 submitted one week after NURS 840
c. Decision of final project proposal given
d. Project Proposal defense PowerPoint submitted
e. Due to military deployment, obligations, and COVID, the project leader took
a absence from the DNP program in December 2018 and returned Fall 2020 D
Term.
5. Phase 2 components completion in Fall 2020
a. Changed scholarly project into an Integrative Review and developed new
clinical questions.
b. Completed an updated integrative search of articles that addressed the impact
of the healthcare provider's role in gaining patient acceptance of the HPV
vaccine.
6. Phase 3 components completion in Spring 2021 (NURS 842)
7. Phase 4 components completion in Spring 2021 (NURS 843)
a. Integrative Review sections 1-2 completed
b. First defense completed
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c. Submitted IRB application for approval
8. Final Phase Summer 2021 (NURS 844)
a. IRB approval
b. Integrative Review sections 3-5 completed
c. Edited final Integrative Review sections 1-5
d. Final Defense
e. Submit final Integrative Review manuscript
f. Send Integrative Review to Scholar's Crossing
Section Four: Discussion
The purpose of the integrative review was to examine the impact of the provider on
gaining the patient's acceptance of the HPV vaccine and the subsequent initiation of the vaccine
series. The expected outcome of the integrative review was to identify evidence-based strategies
in the literature that providers could use to gain patient’s acceptance of the HPV vaccine and its
subsequent initiation as well as to provide recommendations to providers for future practice
among adolescents and young adults. The three themes that emerged from the literature review
were HPV vaccine hindrance, educational strategies, and compliance strategies. These themes
were consistent throughout the reviewed articles.
Barriers and attitudes, vaccine safety and cost, relationship and sexual activity status, and
parent versus provider recommendation were cited as reasons behind a hesitancy to vaccinate.
Questions about HPV vaccine safety and durability of protection was common hindrances to
vaccinating. HPV vaccinations have remained low compared to other adolescent vaccinations.
However, there has been a vast amount of evidence-based research that supports the high
efficacy and safety profile of the HPV vaccine. Increasing HPV vaccination rates has been one of
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the most profound opportunities for cancer prevention. Current research supports the efficacy
and safety of the HPV vaccine and its significant role in combating HPV infections that may lead
to cancer.
Scientific experts have carefully studied the HPV vaccine, and its safety is continually
monitored. This is not a new vaccine, and, for years, the HPV vaccine, has been shown to be
effective and safe. The HPV vaccine has a similar safety profile to the meningococcal and Tdap
(Tetanus, Diphtheria, Pertussis) vaccines. Like other vaccine shots, side effects can happen, but
most are mild, primarily produce pain or redness in the arm, and have not been associated with
any long-term side effects.
Since 2006, about 57 million doses of HPV vaccine have been distributed in the US, and
in the years of HPV vaccine safety studies and monitoring, no serious safety concerns have been
identified (Cummings et al., 2012). There is no data to suggest that receiving the HPV vaccine
has an effect on future fertility. However, HPV infection can cause cervical cancer, and the
treatment of cervical cancer can leave women unable to have children. Thus, vaccination against
HPV infection is necessary to combat this type of cancer in women.
More research is needed to enhance the understanding of the HPV vaccine and how to
implement vaccination campaign changes in healthcare organizations to make this kind of
vaccine mandatory, similar to the measles, mumps, and rubella vaccine. The CDC has used data
collected from the National Health and Nutrition Examination Survey to determine the
prevalence of HPV infection before and after HPV vaccine introduction. HPV prevalence
declined by half after vaccine introduction in 14-19-year-olds. The study showed that the vaccine
was effective when the vaccination series was complete (Cummings et al., 2012).
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The cost of the HPV vaccination was identified as a hindrance to vaccine uptake. The
completion of the HPV vaccine series can cost upward of $490 (Pearson et al., 2014). Although
insurance plans fully cover the cost of routinely recommended vaccinations through the
American Care Act, clients can have to pay out-of-pocket. This cost can hinder vaccination;
however, providers must identify adolescent clients that may have out-of-pocket costs and
connect them with the federal VCF program to cover the full cost of the vaccines. Ultimately, the
cost of treatment for complications of HPV would most likely be greater than the initial cost of
vaccinating individuals to ensure that they do not acquire HPV (Pearson et al., 2014).
The annual estimated cost of HPV-associated diseases in the US is eight billion dollars,
including 6.6 billion due to routine screening. With new technologies, it is hoped that there can
be more efficient screening, augmented by more organized screening systems, and vaccination
leading to reduced screening costs. Estimates of the direct medical costs attributable to HPV
infection can help quantify the economic burden of HPV complications and illustrate the
economic benefits of HPV vaccination.
A National Immunization Survey conducted by Stokely et al. (2015) cited that hesitancy
of vaccination uptake by parents was due to a lack of knowledge about HPV infections and the
vaccine. The association of the HPV vaccine with sexual activity contributes to the hesitancy due
to parents fearing that the vaccination condones sexual activity. However, during the integrative
review, there was no evidence to suggest that receiving the vaccine led to sexual relationships.
Parents may be concerned that allowing their children to receive the HPV vaccine will be seen
by children as permission to have sex. However, multiple studies have determined that girls who
receive the HPV vaccine do not engage in sexual intercourse sooner than their peers who do not
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receive the HPV vaccine. These studies have further shown that receiving the HPV vaccine does
not lead to children being more likely to start having sex at a younger age (Stokely et al., 2014).
A vast amount of research studies have identified that the key to increasing HPV
vaccination rates is recommendations from healthcare providers. Healthcare providers need to
develop communication strategies to increase knowledge regarding cancer prevention benefits,
efficacy, and safety of HPV vaccines to facilitate understanding in clients. These providers can
additionally implement clinic policies that can influence vaccinations. The National Foundation
for Infectious Diseases (2014) has published a call-to-action report for U.S healthcare providers
that has addressed key strategies providers can take to increase HPV vaccinations, thus reducing
the burden of HPV-related cancers. Healthcare providers should, 1) recommend the HPV vaccine
with the same strengths and conviction used to recommend other adolescent vaccines, 2)
educate themselves about HPV infections and HPV vaccines, 3) inform their colleagues to
ensure that all staff throughout the practice deliver the same HPV messages, 4) communicate
vaccination benefits to parents and adolescents at each opportunity, 5) make vaccination
procedures routine and focus on ways to reduce missed opportunities (NFID, 2014, p. 2).
After reviewing the literature, to improve HPV vaccination rates, there needs to be
educational strategies incorporated within healthcare practices to educate healthcare providers,
adolescents, young adults, and their parents and guardians about the importance of HPV
vaccinations. When healthcare providers are adequately informed about HPV, the benefits,
safety, and efficacy of the vaccine, vaccination rates will increase worldwide. Following a
practice model that incorporates HPV education will facilitate adolescents and young adults
making informed decisions about the uptake of the vaccine. Education strategies such as
educational video presentations, education pamphlets and brochures, and interactive apps are key
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educational strategies that can facilitate understanding HPV infections and the positive effect of
the HPV vaccine.
There is a vast amount of research evidence that supports various compliance strategies
to increase HPV vaccination rates. Compliance strategies, as multiple studies have emphasized,
are vital for supporting healthcare vaccination reminder systems. Tools such as postcard
messages, EHR reminders, automated phone calls, and email and text message reminders play an
integral role in increasing immunization adherence to support HPV disease prevention. These
compliance strategies are effective at increasing rates of HPV vaccine completion by reaching
patients who initiate the HPV vaccine series. The use of these compliance strategies and other
key vaccination strategies are positively correlated with improved care processes related to HPV
vaccination. Each of these compliance strategies has seen success during targeted vaccination
initiatives (NFID, 2014). Promoting these strategies and making HPV vaccination a priority for
adolescent and young adult healthcare will help protect this age demographic throughout their
lives.
Implications for Practice
The ACIP recommends HPV vaccination for young adult females and males to prevent
HPV-related cancers and genital warts. As this prevention mechanism continues to be
disseminated, it is necessary to monitor the uptake of this vaccine. Young adults represent an
essential population for HPV vaccination efforts and surveillance due to their increased risk for
HPV infection and this demographic representing a priority population for follow-up HPV
vaccination.
Survey data from 2013 was used to assess the association of demographic variables with
HPV vaccine uptake among college females and males. Thompson, Vamos, Vazquez-Otero et al.
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(2016) followed college females and males (aged 18-21 years) for four years concerning
vaccination rates. A significantly higher proportion of females received at least one dose of the
HPV vaccine than males (59.0% females, 29.8% males; p-value < .010). Rates of HPV
vaccination for females were more than double the rates for males between Fall 2009 and 2011.
While female rates continued to surpass male vaccination rates in 2012 and 2013, both groups
experienced increases in HPV vaccination rates from 2009 to 2013.
Increases in HPV vaccination rates over the five years were evident for all demographic
subgroups. The most significant difference in vaccination rates for females was for women in the
22-26 age category. For both genders, younger age was associated with HPV vaccination. For
females, aged 18-21 years were 1.49 times more likely to be vaccinated than 22 to 26-years old
females. This effect was more pronounced for males, with 18 to 21-year-old males being 2.26
times more likely to be vaccinated than 22 to 26-year-old males (Thompson, Vamos, VazquezOtero et al., 2016).
Continued research in HPV vaccination for adolescents and young adults is needed to
develop evidence-based guidelines to ensure proper vaccination coverage. Continuous
educational awareness about the HPV vaccine, its safety, efficacy, and long-term health impact
being provided to the provider, the adolescent, and the adolescent’s guardian is imperative. This
is essential to increasing and sustaining HPV vaccination rates and allowing for long-lasting and
effective vaccination coverage for adolescents and young adults. “HPV vaccination rates among
adolescents did not meet the Healthy People 2020 goal of 80% coverage” (Gilkey et al., 2015, p.
181). Missing this goal places adolescents and young adults at risk for HPV health disparities
such as cancer.
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The literature has suggested that the healthcare provider's recommendation for
vaccination is key to endorsement and acceptance. "Improving healthcare providers'
communication is among the most important strategy for increasing HPV vaccine uptake in the
US" (Gilkey et al., 2015, p. 181). Therefore, it is crucial that providers seek to improve their
counseling encounters and strategies with adolescents and parents to integrate these vaccines into
practice. When providers start to assess, educate, and plan at each opportunity during an
adolescent's visit, vaccination rates should improve. Predictive factors of HPV vaccine uptake
are a “strong physician recommendation, being a student, and perceiving the importance of the
HPV vaccine” (Thompson, Vamos, Vazquez-Otero et al., 2016, p.97).
Limitations
A limitation of this integrative review was that the article search was restricted to
English-language publications. Therefore, the results are difficult to generalize beyond Western
European, Australian, and North American populations. Furthermore, a majority of the reviewed
studies comparing vaccine hindrance, educational strategies, and communication strategies in
promoting HPV vaccination were conducted in the US. Given that social norms and beliefs differ
by culture, care must be exercised when extrapolating the findings of this review to other
populations.
Dissemination
Contributing to ongoing evidence on strategies to improve HPV vaccination uptake, this
manuscript will be disseminated through a nursing journal to facilitate HPV vaccination
education among healthcare providers. Enhancing healthcare providers’ knowledge of the HPV
vaccine promotes HPV vaccination among adolescents and young adults. The author will
promote this topic to support the HPV vaccination initiative and awareness of HPV infection
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while positively impacting the educational strategies for preventing this virus. The integrative
review will be published and made available for viewing through the Liberty University Library
Scholars Crossing.
Summary
In conclusion, extensive research for this integrative review identified that the US lags in
HPV vaccine coverage compared with other countries. A vast amount of evidence-based
research on HPV prevalence has supported the efficacy of the vaccine in reducing HPV-related
cancers. Completion of HPV vaccinations is an effective cancer prevention strategy. A lack of
HPV vaccination leads to adolescents and young adults being exposed to potential HPV cancers.
Properly vaccinating adolescents and young adults has the potential to prevent unnecessary
suffering and death related to HPV infection. The research studies in this integrative review have
supported that the HPV vaccine has great potential to prevent cervical and other anogenital
cancers. Vaccine uptake research suggests educational programs assist in increasing HPV
vaccination rates; thus, healthcare providers must promote and educate adolescents and young
adults on the ACIP HPV vaccination recommendation, using the vaccine as primary prevention
of HPV infections. In addition, this will assist in decreasing the astronomical healthcare cost of
treating HPV infections in the future.
Current HPV vaccine coverage is currently below what is required to see effects on HPVrelated morbidity and mortality. Research on improving HPV vaccine coverage will continue to
remain at the forefront of improving HPV vaccine uptake and completion. This integrative
review highlighted the importance of HPV education among parents and PCPs to increase
knowledge about HPV infection, thus promoting vaccine uptake and preventing HPV-related
cancers. Key points of the integrative review include, that HPV vaccines are the most effective
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and safest way to protect against HPV infection. Education on the benefits of HPV vaccination is
key to increasing vaccination rates, and providers' confidence in the vaccine benefits motivates
HPV vaccination among the studied population.
Key steps to improving HPV vaccination rates hinges on making HPV vaccination a
public health priority. Healthcare providers can lobby for adequate reimbursement for HPV
vaccines, improved administration, and removing barriers to paying for HPV vaccines.
Currently, HPV vaccination is not a part of the Healthcare Effectiveness Data and Information
Set (HEDIS), a set of widely used performance measures to manage care. Expansion of HEDIS
measures regarding HPV vaccination to include adolescent males and young adults could be
beneficial for increasing vaccinations among these groups. Developing a centralized
immunization information system that is interoperable can promote and facilitate HPV
vaccination.
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Appendix B: Level of Evidence Table

Author

Study Purpose

Sample

Methods

1

Alexander, A. B.,
Best, C.,
Stupiansky, N., &
Zimet, G. D.
(2015). A model
of health care
provider decision
making about
HPV vaccination
in adolescent
males. Vaccine,
33(33), 40814086.
https://doi.org/10.
1016/j.vaccine.20
15.06.085

Identify health care
provider (HCP)
knowledge,
attitudes, and
behaviors regarding
adolescent male
HPV vaccination,
one year, after
routine vaccination
of adolescent males
was recommended.

20
providers,
mostly
female
(n=15)
and white
(n=15),
practicing
pediatric
from one
to 35
years

Qualitativ
e Design
Semistructured
Interviews

2

Bae, J., Ford, E.
W., Wu, S., &

To explore the
relationships among

The study Crossanalyzed 3 sectional

Article

Study
Limitations
The sample
size limited
the
generalizabilit
y of the
findings,
which may
not be
applicable to
different
groups of
HCPs.
Additionally;
sites were
with high
adolescent
vaccination
rates and a
high
proportion of
patients on
state-funded
insurance
programs.
The sample
size was not

Study Results

LOE

Use as Evidence to
Support a Change?

Providers did not
routinely
recommend HPV
vaccine due to
lack of
knowledge, lack
of trust in vaccine
effectiveness,
discomfort in
discussing sexual
orientation and
STDs with
adolescents. HCP
had a positive
opinion about
HPV vaccine and
offered it to most
of their male
patients

Level
III.

Yes, the results from
this study may help to
inform the
development and
evaluation of
interventions for
physicians to increase
vaccine uptake and
may inform future,
larger scale, research
in diverse settings to
gain a better
understanding of
physician knowledge,
attitudes, and practice
around HPV
vaccination.

Analyses
indicated that

Level
III

Yes, using clinical
reminders is strongly
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3

Huerta, T. (2017).
Electronic
reminder's role in
promoting human
papillomavirus
vaccine use. The
American Journal
of Managed Care,
23(11), e353e359.
https://pubmed.nc
bi.nlm.nih.gov/29
182355/

HER adoption,
clinical reminder
use, and HPV
immunization rates.

Bednarczyk, R.
A., Davis, R.,
Ault, K.,
Orenstein, W., &
Omer, S. B.
(2012). Sexual
activity-related
outcomes after
human
papillomavirus
vaccination of 11to 12-year-olds.
Pediatrics,
130(5), 798-805.

This study evaluated
sexual activityrelated clinical
outcomes after
adolescent
vaccination.

adolescent
even
visit
distributed.
samples
during
20072012. And
3 visits
with
female
patients
aged 11 to
26 years
and male
patients
aged 11 to
21 years.
Total:
(25,573
visits).
Study
Retrospect Limitations
included
ive Cohort included:
1398 girls Study
conducted by
(493 HPV
using a
vaccineretrospective
exposed;
analysis of
905 HPV
administrative
vaccinedata. The use
unexposed
of this type of
).
data precludes
an assessment
of motivations
for care.
Population

62
compared with
physicians
without clinical
reminder
functions,
physicians with
clinical reminder
functions were
more likely to
order HPV
vaccines. Clinical
reminder
functions were
particularly
effective at
increasing HPV
vaccine use
among
adolescent males.
Risk of the
Level II
composite
outcome (any
pregnancy/sexuall
y transmitted
infection testing
or diagnosis or
contraceptive
counseling) was
not significantly
elevated in HPV
vaccine-exposed
girls relative to
HPV vaccine-

associated with higher
vaccination rates for
human papillomavirus
(HPV).

HPV vaccination in
the recommended ages
was not associated
with increased sexual
activity-related
outcome rates.
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https://doi.org/10.
1542/peds.20121516

4

Bhatta, M. P., &
Phillips, L.
(2015). Human
papillomavirus
vaccine
awareness,
uptake, and
parental and
health care
provider
communication
among 11- to 18year-old
adolescents in a
rural Appalachian
Ohio county in
the United States.
The Journal of
Rural Health,
31(1), 67-75.
https://doi.org/10.
1111/jrh.12079

Examined HPV
vaccine awareness
and uptake, and
communication with
a parent/healthcare
provider

1299
Cross
participant sectional
s, grades
survey
6-12.
51.9%
were male
and 90.3%
were whit
in rural
Appalachi
an Ohio
county.

63
was restricted
in terms of
age at vaccine
uptake, which
may limit our
ability to
generalize
outside of this
age range.
Limitation
includes being
conducted in
only one
county in
Appalachian
Ohio; thus,
the
generalizabilit
y to a wider
region may be
limited. study
also did not
include a
question on
intention to
get
vaccinated,
which could
have provided
an additional
layer of
information,

unexposed girls
(adjusted
incidence rate
ratio: 1.29, 95%
confidence
interval [CI]: 0.92
to 1.80

Despite the strong Level
link between
III
parental and
health care
provider
communication
and HPV vaccine
uptake., the levels
of communication
remain low in this
population.

Yes, these findings
suggest that need for
public health
education programs
targeting the health
care providers, the
parents, and the
adolescents to improve
awareness,
knowledge, and HPV
vaccine uptake.
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64

5

Cassidy, B.,
Braxter, B.,
CharronProchownik, D.,
& Schlenk, E. A.
(2014). A quality
improvement
initiative to
increase HPV
vaccine rates
using an
educational and
reminder strategy
with parents of
preteen girls.
Journal of
Pediatric Health
Care, 28(2), 155164.
https://doi.org/10.
1016/j.pedhc.201
3.01.002

To determine if an
evidence-based
educational brochure
and reminder system
can increase HPV
vaccine uptake.

24 parents
of preteen
girls from
a private
pediatric
practice
(cohort)
and a
historical
control
group of
29 parents

Quasiexperimen
tal
retrospecti
ve design

Using the
quasiexperimental
design did not
allow the
researcher to
say with
confidence
that the
intervention
caused the
increase in
HPV vaccine
uptake and
dose
completion

HPV vaccine
Level II
uptake rate was
75% in the cohort
and 24.1% in
control group.
Parents who
received the
clinical protocol
had a
significantly
greater HPV
vaccine uptake
rate than the
parents in the
control group.
Completion rates
were 62.5% in the
cohort and 6.9%
in control group.

Yes, The evidencebased educational and
reminder strategy for
parents of this preteen
age group significantly
improved HPV
vaccine uptake and
dose completion.

6

Cheng, L., Wang,
Y., & Du, J.
(2020). Human
papillomavirus
vaccines: An
updated
review. Vaccines,
8(3), 391.
https://doi.org/10.

Researchers present
the updated
information about
current HPV
vaccines, focusing
on vaccine coverage
and efficacy

N/A

Survey
Review

N/A

HPV vaccines
significantly
decreased HPV
infection and
HPV related
diseases. With the
improvement in
vaccine coverage
and the
introduction of

More efforts should be
put into increasing the
vaccine’s coverage,
especially in low- and
middle-income
countries. Provision of
education on HPV and
vaccination is one of
the most important

Level
V
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3390/vaccines803
0391

7

Chesson, H. W.,
Spicknall, I. H.,
Bingham, A.,
Brisson, M.,
Eppink, S. T.,
Farnham, P. G.,
Kreisel, K. M.,
Kumar, S.,
Laprise, J.,
Peterman, T. A.,
Roberts, H., &
Gift, T. L. (2021).
The estimated
direct lifetime
medical costs of
sexually
transmitted
infections
acquired in the
United States in
2018. Sexually
Transmitted
Diseases, 48(4),
215-221.

Estimating the
lifetime medical
costs attributable to
sexually transmitted
infections (STIs)
acquired in 2018,
including sexually
acquired human
immunodeficiency
virus (HIV).

NA

Quantitati
ve Study

Scarcity of
data to inform
the model
parameters.19
,20,43–46.
Given data
limitations,
they did not
apply agespecific
lifetime cost
estimates.

pan-gender
vaccination
programs, better
protection against
HPV infections
and fewer HPVrelated cancer
cases are
expected. T
Incident STIs in
Level
2018 imposed an III
estimated $15.9
billion (25th–75th
percentile: $14.9–
16.9 billion) in
discounted,
lifetime direct
medical costs
(2019 US
dollars). Most of
this cost was due
to sexually
acquired HIV
($13.7 billion)
and HPV ($0.8
billion). STIs
among 15- to 24year-olds
accounted for
$4.2 billion
(26%) of the cost
of incident STIs.

methods to achieve
this.

Incident STIs continue
to impose a
considerable lifetime
medical cost burden in
the United States.
These results can
inform health
economic analyses to
promote the use of
cost-effective STI
prevention
interventions to reduce
this burden.
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https://doi.org/10.
1097/OLQ.00000
00000001380
8

Cummings, T.,
Zimet, G. D.,
Brown, D., Tu,
W., Yang, Z.,
Fortenberry, J. D.,
& Shew, M. L.
(2012). Reduction
of HPV infections
through
vaccination
among at-risk
urban
adolescents.
Vaccine, 30(37),
5496-5499.
https://doi.org/10.
1016/j.vaccine.20
12.06.057

Examined the
impact of HPV
vaccination on HPV
acquisition in a
clinical setting

75 women Cohort
recruited
Study
into the
PC were
matched
with 2
women
selected
from the
387 YWP
participant
s

Temporal
separation of
the two
cohorts
(almost 10
years) and
thus we
cannot totally
exclude the
possibility
that some
other external
factor is not
measured may
have
contributed to
the findings of
reduced HPV
detection of
the
quadrivalent
HPV types or
the
observations
in sexual
behaviors.

Study
demonstrates that
vaccination of
adolescent
females was
associated with
fewer vaccinetype HPV
infections,
suggesting that
the quadrivalent
vaccine was very
effective, even in
the context of
high risk
behaviors and
variable HPV
vaccine
completion. As
expected the
impact of
vaccination was
strongest for
those with two or
more doses of the
vaccine

Level
III

Support the need for
early and catch-up
vaccination in all
adolescent and young
adult women and
serves to remind
clinicians and parents
that vaccination
should be targeted for
all at 11-12 years of
age to maximize its
impact rather than
waiting until the
adolescent is older. In
addition, we found
evidence that the
vaccine did not
increase sexual risk
behaviors. This
evidence, however, is
somewhat limited and
larger prospective
studies may help
further to understand
whether, and in what
way, HPV vaccination
influences sexual
behaviors.
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9

Francis, D. B.,
Cates, J. R.,
Wagner, K. P. G.,
Zola, T., Fitter, J.
E., & CoyneBeasley, T.
(2017).
Communication
technologies to
improve HPV
vaccination
initiation and
completion: A
systematic
review. Patient
Education and
Counseling, 100(
7), 12801286. https://doi.o
rg/10.1016/j.pec.2
017.02.004

Systematic review
that examines the
effectiveness of
communication
technology
interventions on
HPV vaccination
initiation and
completion.

Twelve
relevant
studies
were
identified
with a
total of
38,945
participant
s.

Systemati
c
Randomiz
ed Review

10

Fu, L. Y.,
Bonhomme, L.,
Cooper, S. C.,
Joseph, J. G., &
Zimet, G. D.
(2014).
Educational
interventions to
increase HPV
vaccination
acceptance: A

The purpose of the
current review is to
summarize and
evaluate the
evidence for
educational
interventions to
increase HPV
vaccination
acceptance.

Identified Systemati
33 studies c Review
of HPV
vaccinatio
n
educationa
l
interventio
ns: 7
tested the
effectiven

67
Studies had to
be published
in order to be
included;
thus, it is
possible that
studies with
less
impressive
results were
excluded.
Could not
assess the
efficaciousnes
s of
technologybased
interventions
relative to
humandelivered
interventions.
Search was
restricted to
Englishlanguage
publications.
Vast majority
of reviewed
studies
comparing
different
message

The interventions Level
were delivered
V
using several
different methods,
including EHR
(i.e.
recall/reminder)
prompts, text
messaging,
automated phone
calls, interactive
computer videos,
and email.
Vaccine initiation
and completion
was greater for
technology-based
studies relative to
their control
conditions.

There is evidence that
interventions utilizing
communication
technologies as their
sole or primary mode
for HPV vaccination
intervention delivery
may increase
vaccination coverage.
Communication
technologies hold
much promise for the
future of HPV
vaccination efforts,
especially initiatives in
practice-based
settings.

33 studies of
HPV vaccination
educational
interventions was
identified: 7
tested the
effectiveness of
interventions with
parents, 8 with
adolescents or
young adults, and

Given the association
between HPV
vaccination
acceptance and
individual knowledge,
attitudes and beliefs,
findingeffectiveHPVv
accinationeducationali
nterventionsisessential
to reducing HPV-

Level
V
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systematic
review. Vaccine,
32(17), 19011920.
https://doi.org/10.
1016/j.vaccine.20
14.01.091

11

Getrich, C. M.,
Broidy, L. M.,
Kleymann, E.,
Helitzer, D. L.,
Kong, A. S.,
Sussman, A. L.,
& RIOS Net
Clinician. (2014).
Different models
of HPV vaccine
decision-making
among adolescent

Examine actual
vaccination
decision-making
processes among
clinicians, parents,
and adolescents to
identify strategies to
enhance HPV
vaccination uptake.

68

ess of
interventio
ns with
parents, 8
with
adolescent
s or young
adults and
18
compared
the
effectiven
ess of
different
message
frames.

frames for
HPV
vaccination
education
were
conducted in
the U.S.
(72%).

Hispanic
Mixedmothers
method
and
design
daughters
ages 1218,
healthcare
clinicians,
22
questionna
ires and

Clinical
settings
nationwide
may be
limited
because of the
subjects that
were used.
Small sample
size and
difference in
vaccine

18 compared the
effectiveness of
different message
frames in an
educational
intervention
among
adolescents,
young adults or
their parents.
Well-designed
studies
adequately
powered to detect
change in vaccine
uptake were rare
and generally did
not demonstrate
effectiveness of
the tested
intervention.
Findings
demonstrated
three aspects of
vaccine delivery
that were similar
across clinics;
availability
/supply of
vaccine.
Identified three
decision-making
stages (pre-

associated morbidity
and mortality.

Level
IV

Yes, Factors other race
and ethnicity, such as
education,
socioeconomic status,
and health care access
demonstrates how
important its role in
HPV vaccination
decisions. This can
better equip clinicians
to explain benefits.
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girls, parents, and
health-care
clinicians in New
Mexico. Ethnicity
& Health, 19(1),
47–63.
https://doi.org/10.
1080/13557858.2
013.857767

12

Gilkey, M. B.,
Moss, J. L.,
Coyne-Beasley,
T., Hall, M. E.,
Shah, P. D., &
Brewer, N. T.
(2015). Physician
communication
about adolescent
vaccination: How
is human
papillomavirus
vaccine different?
Preventive
Medicine, 77,
181-185.
https://doi.org/10.
1016/j.ypmed.201
5.05.024

30
interviews

To identify
opportunities for
improving
physicians'
recommendations
for HPV vaccination

776
physicians
(53%
pediatricia
ns, 47%
family
medicine
physician

Crosssectional
Online
Survey

69
delivery
across the two
clinics sites
that
influenced
experiences in
vaccine
decision
making that
they did not
detect.
Limitations
included a
modest
response rate,
which is a
common
challenge for
physician
surveys. Selfreport nature
of physician
communicatio
n variables,
such as the
strength of
vaccine
endorsement
because social
desirability
may have
prompted
physician to

encounter,
encounter, and
post-encounter)
though they found
a distinct
difference in
decision making
processes at the
two sites.

Above threequarters of
physicianreported
recommending
HPV vaccine as
highly important
for patients ages
11-12. 13% of
physicianperceived HPV
vaccine as being
highly important
to parents, which
was or fewer than
perceived
parental support
for Tdap. The
physician
reported that
discussing HPV
vaccine took

Level
IV

Yes, the findings
suggest that primary
care physicians
perceived HPV
vaccine discussions to
be burdensome,
requiring more time
thus less support of
HPV vaccinations than
other adolescent
vaccines.
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70
overestimate
their support
for vaccines

13

Groom, H. C.,
Irving, S. A.,
Caldwell, J.,
Larsen, R.,
Beaudrault, S.,
Luther, L. M., &
Naleway, A. L.
(2017).
Implementing a
multipartner HPV
vaccination
assessment and
feedback
intervention in an
integrated health
system. Journal
of Public Health
Management and
Practice, 23(6),
589-592.
https://doi.org/10.
1097/PHH.00000
00000000562

To provide a guide
for implementing a
multipartner
intervention to
increase HPV
vaccine initiation
rates.

Nine
Literature
primary
Review
care
facilities
within the
Kaiser
Permanent
e
Northwest
health
care
system

Coordination
of
presentations
to the facility
health care
teams, given
their man
competing
priorities.
Missed
opportunities
from clinical
staff members
because of
parental
declination of
vaccination
rather than
lack of
provider
recommendati
on.

almost twice as
long as discussing
other
immunizations.
Most 70% of
physician
discussed HPV
last.
Twelve months
Level
post intervention, V
HPV dose 1
vaccination
coverage
increased from
71% to 72%
among females
and from 65% to
68% among
males.

Yes, this collaborative
approach is critical to
engaging leadership
and enlisting support
from military
leadership and to
developing
appropriate material
for military personnel.
Information provided
can be used as a guide
for conducting
assessment and
feedback interventions
focused on HPV
vaccination initiation.

ACCEPTANCE AND INITIATION OF THE HPV VACCINE
14

Hofstetter, A. M.,
Barrett, A.,
Camargo, S.,
Rosenthal, S. L.,
& Stockwell, M.
S. (2017). Text
message
reminders for
vaccination of
adolescents with
chronic medical
conditions: A
randomized
clinical trial.
Vaccine, 35(35),
4554-4560.
https://doi.org/10.
1016/j.vaccine.20
17.07.022

Purpose of the study
was to compare the
effect of plain vs
educational text
message reminders
on receipt of needed
vaccines among
adolescents with
chronic conditions.

295
parents of
chronic
medical
condition,
adolescent
s ages 1118; 59.3%
Spanish
speaking;
77.6% had
adolescent
s with
medical
condition
who were
13-17
years
92.5%
were
publicly
insured

Randomiz
ed control
clinical
trial

15

Huh, W. K.,
Joura, E. A.,
Giuliano, A. R.,
Iversen, O., de
Andrade, R. P.,
Ault, K. A.,
Bartholomew, D.,
Cestero, R. M.,

Aimed to report
efficacy of the
9vHPV vaccine for
up to 6 years
following first
administration and
antibody responses
over 5 years.

Safety
study of
the
9vHPV
vaccine
study at
105 study
sites in 18

Randomis
ed,
doubleblind,

71
Given the
unavoidable
logistical gap
between
enrollment
and
randomization
,
approximately
one-quarter of
enrolled
adolescents
received all
needed
vaccines and
were
excluded.
some parents
did not
complete
additional
survey items,
which could
have biased
the findings.
The study was
limited in
duration.
Limitedly the
use of an
active control
group,

Plain text
messages more
effective than
educational text
messages in short
term.

Level I

Plain text message
vaccine reminders
appear to have a
positive effect
compared to
educational ones in the
short-term and for
certain families.
Highlight the potential
for engaging
subspecialty providers,
although they face
unique challenges, and
using other novel
technology-based
approaches.

In the perLevel I
protocol
population, the
incidence of highgrade cervical,
vulvar and
vaginal disease
related to HPV

This study shows that
many important
individual clinical and
global public health
outcomes are
prevented by 9vHPV
vaccination: HPV
infection, abnormal
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Fedrizzi, E. N.,
Hirschberg, A. L.,
Mayrand, M.,
Ruiz-Sternberg,
A. M., Stapleton,
J. T., Wiley, D. J.,
Ferenczy, A.,
Kurman, R.,
Ronnett, B. M.,
Stoler, M. H.,
Cuzick, J., . . .
Luxembourg, A.
(2017). Final
efficacy,
immunogenicity,
and safety
analyses of a
nine-valent
human
papillomavirus
vaccine in women
aged 16–26 years:
A randomized,
double-blind trial.
The Lancet,
390(10108),
2143-2159.
https://doi.org/10.
1016/S01406736(17)31821-4

countries.
Women
aged 16–
26 years
old.
Recruited
and
randomly
assigned
14215
participant
s.

72
31, 33, 45, 52,
and 58 was 0·5
cases per 10000
person-years in
the 9vHPV and
19·0 cases per
10000 personyears in the
qHPV groups,
representing
97·4% efficacy
(95% CI 85·0–
99·9). HPV 6, 11,
16, and 18 GMTs
were non-inferior
in the 9vHPV
versus qHPV
group from month
1 to 3 years after
vaccination. No
clinically
meaningful
differences in
serious adverse
events were noted
between the study
groups. 11
participants died
during the study
follow-up period
(six in the 9vHPV
vaccine group and
five in the qHPV

cytology, histological
disease, and treatment
procedures. The robust
methods we used
strengthened the
clinical evidence to
support vaccination
for the prevention of
HPV-related cancers.
This data show that
prophylactic
administration of the
9vHPV vaccine is
highly efficacious in
preventing infection,
cervical cytological
abnormalities,
histologically detected
high-grade disease,
and medical
procedures associated
with vaccine HPV
types. Broad
immunization of
adolescent populations
might result in such a
substantial decrease in
highgrade cervical
disease that the
evaluation of optimal
screening algorithms
in women vaccinated
with the 9vHPV
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Johnson-Mallard,
V., Darville, G.,
Mercado, R.,
Anderson-Lewis,
C., & MacInnes,
J. (2019). How
health care
providers can use
digital health
technologies to
inform human
papillomavirus
(HPV) decision
making and
promote the HPV
vaccine uptake
among
adolescents and
young adults.
BioResearch
Open Access,
8(1), 84-93.
https://doi.org/10.
1089/biores.2018.
0051

the purpose of this
research study is to
determine how
health care providers
can utilize digital
health technologies
(such as the internet,
mobile phones, short
message service
[SMS] text
messages, and
mobile apps) to
increase individual
risk perception of
the HPV virus,
increase awareness
about the HPV
vaccine, overcome
barriers to the HPV
vaccine, and help
adolescents and
young adults make
informed decisions
to get the HPV
vaccine.

A
convenien
ce sample
of 210
students
completed
an online
survey.
Participant
s were 18–
25 years
of age
(88%),
female
(85%),
Caucasian
(60%),
and never
been
diagnosed
with HPV
(92.9%).

Ramdomi
zed
Sampling
Survey

73
vaccine group);
none of the deaths
were considered
vaccine-related.
No limitations The findings of
Level
noted
this study
III
indicated that
work is needed in
the acceptance of
social media,
SMS text
messaging, and
mobile Apps as
preferred digital
health
technologies
beyond the
internet. Health
care providers can
educate parents
and students with
regard to
navigating the
health system to
obtain health
information by
using text
messages and
mobile apps,
easily and
effectively.

vaccine will be
necessary.

Growing evidence
support using digital
health technologies to
inform decision
making to increase
HPV risk perception
and promote HPV
vaccine uptake among
adolescents and young
adults. Digital health
technology beyond the
internet and online
websites is warranted
and when used
appropriately can be a
strategic and
successful tool to
inform decision
making, increase
perception, and
promote HPV vaccine
uptake. Text
messaging can be used
to receive updates
from healthcare
providers.
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Krawczyk, A.,
Lau, E., Perez, S.,
Delisle, V.,
Amsel, R., &
Rosberger, Z.
(2012). How to
inform:
Comparing
written and video
education
interventions to
increase human
papillomavirus
knowledge and
vaccination
intentions in
young adults.
Journal of
American College
Health, 60(4),
316-322.
https://doi.org/10.
1080/07448481.2
011.615355

To compare the
efficacy of 2 human
papillomavirus
(HPV) educational
interventions on
increasing HPV
knowledge
and vaccination
intentions in college
students.

Male (n =
60) and
female (n
= 140)
undergrad
uates

Quantitati
ve Study
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Kulczycki, A.,
Qu, H., &
Shewchuk, R.
(2016).
Recommend, but
also discuss:
Different patterns
of physician-

Understand the
extent to which
adherence to clinical
guidelines, as
indicated by the
reported intentions
of PCPs to prescribe
HPV vaccination

Randomiz Survey
ed
Cohort
sampling
Study
design,
301
pretested
questionna
ires

74
High SES of
the sample,
and therefore
results may
not be
generalizable
to a wider
population of
young adults.

Low baseline
knowledge and
intentions were
found across
groups. Post
intervention,
participants in the
written and video
interventions
had significantly
higher knowledge
and intentions
than
the control. No
differences were
found between
written and video
interventions on
knowledge or
intention

Level
III

Yes, written and video
interventions are
equally effective in
educating
about HPV and
increasing young
adults' vaccination
intentions.

Data is selfreported and
could not be
checked
through other
methods,
study assessed
likelihood to

67% of the
Level
respondents said
V
they were likely
to prescribe HPV
vaccination.
14%disagreed
with the statement
that professional

Yes, This study shows
that the perceived lack
of guideline clarity is
associated with lesser
stated likelihood to
prescribe vaccine,
which in turn is
associated with lower
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perceived barriers
to discussing
HPV vaccination
and their
association with
vaccine
administration in
11–12 year-old
girls. Maternal
and Child Health
Journal, 20(12),
2539-2547.
https://doi.org/10.
1007/s10995-0162079-9
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Manhart, L. E.,
Burgess-Hull, A.
J., Fleming, C. B.,
Bailey, J. A.,
Haggerty, K. P.,
& Catalano, R. F.
(2011). HPV
vaccination
among a
community
sample of young
adult women.
Vaccine, 29(32),
5238-5244.
https://doi.org/10.
1016/j.vaccine.20
11.05.024

completed
by family
practitione
rs and
pediatricia
ns

Despite the high
efficacy of the
human
papillomavirus
(HPV) vaccine,
uptake has been
slow
and little data on
psychosocial barriers
to vaccination exist.

Communit
y sample
of 428
women
enrolled in
a
longitudin
al study of
social
developm
ent in
the Seattle
WA
metropolit
an area
were
interviewe

Crosssectional
study
design

75
prescribe
HPV
vaccination
rather than its
actual
administration
, and limited
resources
prevented a
larger survey.

guidelines about
HPV vaccination
offered clear
guidance and
22% of
respondents
categorically
believed in
mandated HPV
vaccination

actual vaccination
rates.

This was a
predominantly
white
population;
thus we were
not able to
carefully
explore racial
disparities.
Additionally,
we did
not measure
several key
factors for
HPV vaccine
uptake
(insurance

19% of women
Level
had initiated
III
vaccination, 10%
had completed the
series, and ∼40%
of unvaccinated
women intended
to get vaccinated.
Belief the vaccine
is <75% effective
was associated
with less
initiation (APR
0.6; 0.4–0.9) or
intention to
vaccinate (APR
0.5; 0.4–0.7).

The HPV vaccine has
great potential to
prevent cervical and
other anogenital
cancers. However,
current vaccine
coverage
estimates are
substantially below
those required to see
population level
effects on HPV-related
morbidity and
mortality and
much remains to be
done to increase HPV
vaccine uptake and
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d about
HPV
vaccine
status,
attitudes,
and
barriers to
HPV
vaccinatio
n in spring
2008 or
2009 at
∼age 22.
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Miller, M. K.,
Wickliffe, J.,
Jahnke, S.,
Linebarger, J., &
Humiston, S. G.
(2014). Views on
human
papillomavirus
vaccination: A
mixed-methods

Conducted a mixedmethods study using
the theory of
planned behavior
framework to
explore attitudes and
beliefs about HPV
vaccination among
urban, economically

Fifty
Mixedadolescent method
s aged 14– study
18 years
were
recruited
from
communit
y-based
organizati

76
coverage,
discussion of
vaccination
with
significant
individuals),
or
where
vaccinated
women had
received the
vaccine and
thus were
unable to
evaluate them.
Finally, the
crosssectional
study design
precludes
conclusions
about
causality
Results may
not be
generalizable
to other
racial/ethnic
groups or
youth outside
of the
Midwest. use
of a

Vaccine initiation
was also less
likely among
cigarette smokers
and
illegal drug users,
whereas intention
to vaccinate was
more common
among women
currently
attending
school or with >5
lifetime sex
partners, but less
common among
women
perceiving low
susceptibility to
HPV.

completion. Focusing
efforts on increasing
knowledge about the
widespread nature of
HPV infection and the
high levels of vaccine
efficacy, along with
peer interventions,
may be most effective.

Less than half (40 Level
%) of participants III
reported receipt
ofC1HPV vaccine
dose. Among
those who had
received 1doses
(20 participants),
seven completed
the series, three

Study indicates a
profound lack of
awareness about HPV
vaccination as well as
the important
influence of parents
among urban,
economically
disadvantaged youth.
Awareness of these
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77

study of urban
disadvantaged
youth. Journal of adolescents.
Community
Health, 39(5),
835-841.
https://doi.org/10.
1007/s10900-0149858-2

ons to
complete
a written
survey
and
participate
in a focus
group

Caucasian
moderator
may have
influenced
communicatio
n among
focus group
participants.

received 1or 2
doses, and 10
could not recall
the number of
doses received.

attitudes and beliefs
can assist public
health officials as well
as providers by
informing specific
interventions to
increase vaccine
uptake

Mohammed, K.
A., Geneus, C.J.,
Osazuwa-Peters,
N., Adjei-Boakye,
E., Tobo, B. B., &
Burroughs, T. E.
(2016).
Disparities in
provider
recommendation
of human
papillomavirus
vaccination for
U.S. adolescents.
Journal of
Adolescent
Health, 59(5),
592-598.
https://doi.org/10.
1016/j.jadohealth.
2016.06.005

Overall
Crossprevalence sectional
of vaccine Survey
recommen
dation was
72.6% for
girls and
51.8 for
boys.
Girls had
a higher
odds of
vaccine
recommen
dation.

The NIS-Teen
data laced
provider
specific
information,
such as
demographic
characteristics
and provider
specials as
well as
barriers to
vaccine
recommendati
on. Could not
confirm
whether
providers
actually
recommended
HPV vaccine
to the
adolescent

This study
Level II
demonstrated
lower HPV
vaccine
recommendation
for boys,
adolescents below
poverty line,
those with lesser
educated mothers,
and those who
live in the South.
Findings indicate
important
disparities in
vaccine
recommendation
that must be
addressed to
achieve optimal
vaccine uptake
among high risk
population.

Yes, this study
highlights significant
disparities in provider
recommendation of
HPV vaccination for
U.S. adolescents.
Findings suggest
possible areas for
tailored interventions
to bridge the gap in
vaccine
recommendation and
uptake in high risk
population.

To determine the
prevalence of and
examine factors
associated with
provider
recommendation of
HPV vaccination for
U.S. adolescents
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Mullins, T. L. K.,
Griffioen, A. M.,
Glynn, S., Zimet,
G. D., Rosenthal,
S. L.,
Fortenberry, J. D.,
& Kahn, J. A.
(2013). Human
papillomavirus
vaccine
communication:
Perspectives of
11–12 year-old
girls, mothers,
and clinicians.
Vaccine, 31(42),
4894-4901.
https://doi.org/10.
1016/j.vaccine.20
13.07.033

Study explored
communication
between 11- and 12
year-old girls,
mothers, and
clinicians regarding
HPV vaccines and
concordance in
reports of maternal
and clinician
communication.

Conducted Qualitativ
individual e
interviews Interview
with 33
girls who
had
received
the
quadrivale
nt HPV
vaccine in
urban and
suburban
clinical
settings,
their
mothers,
and their
clinicians.

78
Interviews
were
conducted
using a
sample from
one
geographic
location.
Participants
may not
remember or
report all of
the
information
that was
discussed
with regard to
HPV
vaccination,
particularly if
discussions
occurred over
several visits.
Some
clinicians
were
interviewed
more than
once; results
could be
skewed by
overrepresentation

From the
Level
perspectives of
VI
both girls and
mothers,
clinicians and
parents were the
preferred sources
of HPV vaccine
information for
girls. Vaccine
efficacy and
risks/benefits of
vaccination were
the most
commonly
reported desired
and actual topics
of discussion by
mothers, girls,
and clinicians.
Clinician
recommendation
of vaccination
was reported by
nearly one-fifth of
girls and nearly
half of mothers.

HPV vaccine efficacy
and safety are
important topics for
clinicians to discuss
with both girls and
mothers; educating
mothers is important
because parents are a
preferred source of
vaccine-related
information for girls.
Because girls may be
missing important
vaccine-related
messages, they should
be encouraged to
actively engage in
vaccine discussions.
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Oldach, B. R., &
Katz, M. L.
(2012). Ohio
Appalachia public
health department
personnel:
Human
papillomavirus
(HPV) vaccine
availability, and
acceptance and
concerns among
parents of male
and female
adolescents.
Journal of
Community
Health, 37(6),
1157-1163.
https://doi.org/10.
1007/s10900-0129613-5

Update information
regarding the
demand, availability,
recommendation,
and barriers of HPV
Vaccination for
males and females in
Appalachia Ohio.

Public
health/im
munizatio
n nurses,
directors
of public
health
nursing,
one public
health
supervisor
of 46
public
health
departmen
ts
identified
as
Appalachi
a
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Patel, D. A.,
Zochowski, M.,
Peterman, S.,
Dempsey, A. F.,
Ernst, S., &
Dalton, V. K.
(2012).

To examine human
papillomavirus
(HPV)
vaccine intent and
the effect of an
educational
intervention on
vaccine uptake

Females
aged 18 to
26
attending
a
university
health
service

79

of these
clinicians
SemiParticipants in
structured the study
questionna provided an
ire with
estimation of
interviews the number of
.
requests for
HPV
vaccines. The
generalizabilit
y of the
results is
limited by
conducting
the study
among health
department
serving only
Appalachia
Ohio.

Randomiz
ed Study

Study focused
on females
seeking
routine health
main-tenance
at a UHS, the
study
population

Health
departments
reported 15
barriers to HPV
vaccination
among patients or
parents of
patients. Some
include lack of
knowledge,
concern about
side effects, the
vaccine may
cause sexual
promiscuity,
vaccine series
completion,
religious beliefs,
and cancer does
not run in my
family.

Level
V

Yes, findings suggest
that parents of males
and parents of females
may have different
informational needs
and may respond to
different messages
when making an
informed decision
about HPV
vaccination for their
children. This can
identify ways to help
clinicians with
pushing for the
vaccination

At baseline, 41%
intended to
undergo HPV
vaccination.
Participants who
were currently
sexually active
and lacked

Level I

Interventions to
increase HPV vaccine
uptake
in college students
should address HPVrelated beliefs and
broader
barriers to vaccination.
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Human
among female
papillomavirus
college students. P
vaccine intent and
uptake among
female college
students. Journal
of American
College Health,
60(2), 151-161.
https://doi.org/10.
1007/s10900-0129613-5

gynecolog
y clinic
(n = 256).

Pearson, A. L.,
Kvizhinadze, G.,
Wilson, N.,
Smith, M.,
Canfell, K., &

Markov
macrosimulation
model, for
an annual
cohort of

Explore the costutility of girls-only
HPV vaccination, to
estimate qualityadjusted life years
(QALYs) gained and

80
may not
reflect the
overall
population of
college-aged
women at our
institution,
women of the
same age
range in other
university
settings, or
women of the
same age
range who do
not attend
college.

Cohort
Randomiz
ed Study

The lack of
local data to
build a
dynamic HPV
infection
model and

supplemental
health insurance
had decreased
intent. Perceived
parental approval
regarding HPV
vaccination,
perceived
vulnerability to
HPV infection,
and belief in
health benefits
of HPV vaccine
were associated
with increased
intent. HPV
vaccine
uptake was low
(5.5%) and did
not differ by
study group.
However,
baseline intent
was significantly
associated with
HPV vaccine
uptake.
The modeling
results indicated
that the estimated
intervention costs
rose with
increasing

Level
III

New evidence of
lower vaccine bulk
prices tendered by
developed countries
becomes available,
future modeling may
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Blakely, T.
(2014). Is
expanding HPV
vaccination
programs to
include schoolaged boys likely
to be value-formoney: A costutility analysis in
a country with an
existing schoolgirl
program. BMC
Infectious
Diseases, 14(1),
351365. https://doi.or
g/10.1186/14712334-14-351

net health system
costs, for girls-only
and girls and boys
vaccination

12-yearolds in
2011

Piedimonte, S.,
Leung, A.,
Zakhari, A.,
Giordano, C.,
Tellier, P., & Lau,
S. (2018). Impact
of an HPV
education and
vaccination
campaign among
Canadian
university

Objective was to
151
determine the level
participant
of knowledge related s
to HPV and cervical
cancer among
university students
and to subsequently
develop a targeted
education and
vaccination
campaign to increase
uptake.

Semistructured
questionna
ire with
interviews

81
thus, our
reliance on
HPV
reduction
results from a
Canadian
dynamic
model.

coverage levels
and when adding
boys to the girlsonly programs.
QALY gained
increased with
higher coverage
levels. The health
sector would get
the best value-formoney by further
improving HPV
vaccination
coverage for girls,
rather than adding
in the vaccination
of boys.

The low
participation
and in-ability
to provide
continuous
services from
residents and
medical
students.

Phase I, 56
participants
responded to a
questionnaire
related to HPV
knowledge and
cervical cancer.
Among these, 29
students were
vaccinated in a 2day resident-run
clinic. Overall,

be worthwhile as it is
likely to suggest
improvements in costeffectiveness

Level
V

HPV vaccination rates
in university students
are readily
increased through
educational
campaigns, of which
personsolicitation proved to
be the most fruitful in
this study.
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students. Journal
of Obstetrics and
Gynecology
Canada, 40(4),
440-446.
https://doi.org/10.
1016/j.jogc.2017.
07.028
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Rand, C.M.,
Vincelli, P.,
Goldstein, N. P.,
Blumkin, A., &
Szilagyi, P. G.
(2017). Effects of
phone and text
message
reminders on
completion of the
human
papillomavirus
vaccine series.
Journal of
Adolescent
Health, 60(1),
113-119.
https://doi.org/10.
1016/j.jadohealth.
2016.09.011

To assess the effect
of phone or text
message reminders
to parents of
adolescents on
(HPV) vaccine
series completion in
Rochester, NY.

Urban
primary
care
clinics,
parents of
adolescent
s ages 1117 ears,
358 in
phone
reminder
group and
391 in text
message
reminder
group

Randomiz
ed
controlled
trials

Study
occurred in
one city in
upstate New
York and had
a limited
sample size.
Moreover,
study
personnel
rather than
office staff
tracked the
data and sent
messages;
thus, further
work is
needed to
implement
sustainable
models of
patient
reminder
recall for

63% felt they
were not at risk of
cervical cancer,
though 88% knew
HPV was the
cause of cervical
cancer.

Identifying barriers to
vaccination can guide
future initiatives to
maximize impact.

In this urban
Level I
population of
parents of
adolescents, text
message
reminders for
HPV vaccine
completion for
those who had
already started the
series were
effective, whereas
phone message
reminders were
only effective for
those enrolled at
dose 1.

More research is
needed to test the
effectiveness of largescale population-level
text message
reminders for
adolescent
immunizations and
office-based
interventions that
could improve rates.
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Real, F. J., Rosen,
B. L., Bishop, J.
M., McDonald,
S., DeBlasio, D.,
Kreps, G. L.,
Klein, M., &
Kahn, J. A.
(2021). Usability
evaluation of the
novel smartphone
application, HPV
vaccine: Same
way, same day,
among pediatric
residents.
Academic
Pediatrics, 21(4),
742-749.
https://doi.org/10.
1016/j.acap.2020.
11.023

Characterize resident
clinicians'
perceptions
regarding the
usability of the HPV
Vaccine: Same Way,
Same Day
smartphone
application (app).
Usability, a critical
aspect of digital
programs to promote
behavior change,
was evaluated.

Fifteen
third-year
pediatric
residents
were
recruited
to
complete
a usability
evaluation
of the
HPV
Vaccine:
Same
Way,
Same Day
app,

Qualitativ
e Study
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Reiter, P. L.,
McRee, A.,

Examining parents'
and adolescents'

Parents of
Adolescen

Mixed
design

83
HPV
vaccination.
There was the
possibility of
self-selection
bias as
participants
with increased
interest in
technologybased
education or
vaccine
delivery
might have
chosen to
contribute and
positively
skewed
results.
Second, they
did not report
the impact of
our
intervention
on patients’
HPV
vaccination
rates.

Survey did
not address

Twenty (51%) of
39 eligible
residents
completed initial
enrollment.
Fifteen (75%) of
the enrolled
residents
completed all
aspects of the
study. Residents
described the app
as interactive,
easy to use,
succinct,
informative,
engaging, and
practical. All
residents would
recommend the
HPV Vaccine:
Same Way, Same
Day app to a
colleague.
Residents
suggested adding
more complex
cases for future
iterations.
Parents and sons
were most

Level II From their
perspective, pediatric
residents reported that
an app using
deliberate practice
principles has the
potential to inform and
advance providers'
counseling skills
regarding the HPV
vaccine.

Level
V

Yes, offering HPV
vaccine in alternative
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Pepper, J. K.,
Chantala, K., &
Brewer, N. T.
(2012).
Improving human
papillomavirus
vaccine delivery:
A national study
of parents and
their adolescent
sons. Journal of
Adolescent
Health, 51(1), 3237.
https://doi.org/10.
1016/j.jadohealth.
2012.01.006

preferences
regarding potential
strategies to increase
HPV vaccination
rates.

t boys 1117
(n=506)
and their
sons
(n=391)

Rutten, L. J. F.,
Sauver, J.L.,
Beebe, T. J.,
Wilson, P. M.,
Jacobson, D. J.,
Fan, C., Jacobson,
R. M. (2017).
Clinician
knowledge,
clinician barriers,
and perceived
parental barriers
regarding human
papillomavirus

Researchers tested
the hypothesis that
clinician knowledge,
clinician barriers,
and perceived
parental barriers
relevant to the
human
papillomavirus
(HPV) vaccination
account for the
variation in vaccine
delivery at the
practice-site level.

n = 280 in
a 27county
geographi
c region

84
other
potentially
important
issues of HPV
vaccination in
alternative
settings, such
as the process
of obtaining
consent for
vaccination.

Crosssectional
Study

Using clinical
data is that
patients may
have had
vaccinations
in other
locations,
which may
lead to an
underestimate
of vaccination
rates.

comfortable with
sons receiving
HPV vaccine in a
doctor's office.
Parents of sons
who had not
visited their
regular health
care providers in
the past year were
more comfortable
with sons
receiving HPV
vaccine at a
public clinic
compared with
parents whose
sons had recent
visits.
A total of 685
Level
clinicians were
V
sent the survey
and 280 returned
the survey
resulting in an
overall response
rate of 41.0%. A
total of 52 clinical
sites were
represented.
Using
administrative
data, we assessed

settings and
administering it with
other recommended
adolescent vaccines
may increase uptake
among adolescent
boys. Parents and sons
may prefer HPV
vaccines be
administered during
brief nurse visits.

Identification of
practice sites with
knowledge gaps and
corresponding lower
rates of vaccination
will guide efforts to
design interventions
that can overcome the
knowledge gaps and
improve HPV vaccine
delivery. Furthermore,
understanding
frequently
encountered negative
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vaccination:
Association with
initiation and
completion rates.
Vaccine, 35(1),
164-169.
https://doi.org/10.
1016/j.vaccine.20
16.11.012
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Smith, L. M.,
Kaufman, J. S.,
Strumpf, E. C., &
Lévesque, L. E.
(2015). Effect of
human
papillomavirus
(HPV)
vaccination on
clinical indicators
of sexual

Suboptimal human
papillomavirus
(HPV) vaccine
coverage in some
jurisdictions is partly
attributed to fears
that vaccination may
increase risky sexual
behavior. We
assessed the effect of
HPV vaccination on

128, 712
8th grade
females
from
Ontario
health
database

Quasiexperimen
tal Design

Limitations
due to only
screening this
geographical
area and not
national.

whether there
were any
significant
differences
between survey
responders and
non-responders
by medical
specialty and
geographic
region. No
differences were
observed by
medical specialty
(P=0.3).
Response rates
were higher in the
Rochester area
and lower in the
southeastern
Minnesota region
(P=0.003).
128,712 were
eligible. They
identified 15,441
(5.9%) cases of
pregnancy and
sexually
transmitted
infection and
found no
evidence that
vaccination

clinician attitudes and
perceived parental
barriers provides
insight into the factors
to be addressed when
designing clinicianand parent-directed
interventions.

Level
V

Yes, strong evidence
that HPV vaccination
does not have any
significant effect on
clinical indicators of
sexual behavior
among adolescent
girls. These results
suggest
that concerns over
increased promiscuity
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behavior among
adolescent girls:
The Ontario grade
8 HPV vaccine
cohort study.
Canadian
Medical
Association
Journal, 187(2),
E74-E81.
https://doi.org/10.
1503/cmaj.14090
0

clinical indicators of
sexual behavior
among adolescent
girls in Ontario.

Staras, S. A. S.,
Vadaparampil, S.
T., Thompson, L.
A., Scherr, C.,
Gurka, M. J.,
Filipp, S. L., &
Shenkman, E. A.
(2020). Postcard
reminders for
HPV vaccination
mainly primed
parents for
providers’
recommendations
. Preventive
Medicine Reports,
20, 101188.
https://doi.org/10.

Assessed the
percentage increase
in HPV vaccine
initiation from
reminders increasing
preventive care
visits or increasing
the likelihood of
vaccine receipt
during preventive
care.

86
increased the risk
of this composite
outcome

2,470
Girls
enrolled in
the trial:
were 11 to
17 years
old,
enrolled in
Florida
Medicaid
or
Children's
Health
Insurance
Program
(CHIP),
had a
regular
office visit

Quasiexperimen
tal
Randomiz
ed Survey

Medicaid and
CHIP data
likely have
incomplete
vaccination
records.
Because we
randomized
postcard
assignment,
the
incompletenes
s in the
vaccination
records
should be
balanced
across arms
and have little

Postcard
messages
primarily
increased HPV
vaccination by
increasing
parents’
receptivity to
providers’ HPV
vaccine
recommendations
. Combining
reminders with
many of the
efficacious
provider-targeted
interventions
(e.g., Brewer’s
announcement

following HPV
vaccination are
unwarranted
and should not deter
from vaccinating at a
young age

Level
III

Decreasing the time
between vaccine
reminders and
preventive care
appointments may
maximize the priming
effect of reminders.
Multi-level
interventions should
consider including
reminders as priming
agents for parents
combined with an
intervention to
increase provider
recommendation
frequency and
strength.
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Thompson, E. L.,
Vamos, C. A.,
Sappenfield, W.
M., Straub, D.
M., & Daley, E.
M. (2016).
Relationship
status impacts
primary reasons
for interest in the
HPV vaccine
among young
adult women.
Vaccine, 34(27),
3119-3124.
https://doi.org/10.
1016/j.vaccine.20
16.04.063

between
July 1,
2011 and
August 1,
2013

The purpose of this
study was to assess
show relationship
status impacts
interest in HPV
vaccination and
primary reasons for
non-vaccination
among 18-26 year
old young women.

The
National
Health
Interview
Survey
2010 was
examined
among
unvaccinat
ed
females,
18–26
years (N =
1457).

Crosssectional
randomize
d survey

87
influence on
the results.
Second, the
postcards
were sent in
2013 to
parents in
Northern
Florida. In
recent years,
HPV vaccine
initiation rates
have
increased, but
remain low
This study
was limited
by selfreported data
for HPV
vaccination
and limitation
of response
rate.

strategy) will
likely produce
stronger
synergistic effects
than combining
reminders with
increased
preventive care
access

Among
Level
unvaccinated
III
women, 31.4%
were interested in
the HPV vaccine.
Women who were
living with a
partner (PR =
1.45, 95%CI
1.06–1.90) and
single (PR = 1.42,
95%CI 1.11–
1.76) were
significantly more
likely than
married women to
be interested in
the HPV vaccine,

Relationship status in
young adulthood
impacts HPV vaccine
interest and decisionmaking among a
national sample of
women. Primary
reasons for noninterest in the vaccine
may be shaped by
attitudes and
knowledge about the
HPV vaccine that
differ by relationship
status. Future research
is needed to elucidate
ways to overcome
relationship status as a
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Thompson, E. L.,
Vamos, C. A.,
Vázquez-Otero,
C., Logan, R.,
Griner, S., &
Daley, E. M.
(2016). Trends
and predictors of
HPV vaccination
among U.S.

The purpose of this
study was to assess
the trends in HPV
vaccination among
U.S. college females
and males from 2009
to 2013, and to
examine whether
predictors for HPV
vaccination differ

Majority
of
responden
ts were
female
(71.1%).
Males
(59.0%
females,
29.8%

Crosssectional
randomize
d Survey

88

Data were
crosssectional,
which limit
the ability to
establish
temporality
between the
time of HPV
vaccination

while controlling
for sociodemographic and
other known risk
factors.
Additionally,
primary reasons
for nonvaccination
differed based on
relationship status
among
uninterested
women (p <
0.01). Women
who were married
were more likely
to cite not
needing the
vaccine compared
to never married
women (p <
0.05).
Females had
Level
nearly double the III
rates of HPV
vaccination
compared to
males over time.
All demographic
sub-groups had
significant
increases in

barrier to HPV
vaccination.

These findings
identified specific
demographic subgroups that need
continued support for
HPV vaccination.
Campus health centers
may be rational
settings to facilitate
clinical opportunities
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college women
between males and
and men.
females.
Preventive
Medicine, 86, 9298.
https://doi.org/10.
1016/j.ypmed.201
6.02.003
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Vanderpool, R.
C., Cohen, E. L.,

Identified correlates
of intent to complete

males.
Ages of
18 and 21
years,
heterosexu
al (92.8%
females,
91.4%
males.
NonHispanic
White
(67.4%
females,
65.2%
males.
Reported
not being
in a
relationshi
p (51.2%
females,
60.3%
males)
and single,
not
married
(93.2%
females,
93.2%
males.
344
CrossYoung
sectional

89
and certain
modifiable
variables
(e.g.,
relationship
and marital
status). Didn’t
specify how
many of the
recommended
three doses of
the HPV
vaccine
participant’s
received.
Measurement
of
race/ethnicity
changed
between study
periods,
which
prohibited the
comparison of
vaccination
continuously
across all
study periods.

vaccine rates over
time, with select
male sub-groups
having more
accelerated
increases (e.g.,
gay). Young age
(18–21 vs. 22–26
years) was a
significant
predictor for HPV
vaccination
among males and
females, while
race/ethnicity was
a predictor of
vaccination
among females
only.

Crosssectional

Positive intent to
complete the

for HPV vaccination
among unvaccinated
college students.

Level
III

Findings suggest the
potential for
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Crosby, R. A.,
Jones, M. G.,
Bates, W., Casey,
B. R., & Collins,
T. (2013). "1-2-3
Pap" Intervention
improves HPV
vaccine series
completion
among
Appalachian
women. Journal
of
Communication,
63(1), 95-115.
https://doi.org/10.
1111/jcom.12001

the vaccine series
and actual series
completion, but also
tested the efficacy of
a DVD intervention
to promote HPV
vaccine series
completion

women
ages 1826 from
an eightcounty
catchment
area of
Appalachi
an
Kentucky
in the
United
States.

Randomiz
ed Study

90
nature of the
baseline
survey does
not allow for
measuring
temporal
changes in
health-related
attitudes and
beliefs, the
influence of
subjective
norms,
perceived
behavioral
control, and
behavioral
intentions.

vaccine series
was indicated by
64.3% of the
women (n=220).
Just over onethird (37.8%) of
the sample
completed the
three-dose series.
Positive intent
was indicated by
58.2% of those
randomized to the
intervention
condition and
70.9% in the
control condition
(p=.014). Nearly
half of the women
(43.3%)
randomized to the
DVD intervention
completed the 3doseseries,
whereas 31.9% of
women assigned
to the comparison
group completed
the series, for a
percent relative
difference of
35.7% (p=.03).

translating this
approach to other
vaccination contexts in
which adherence to a
multiple dosage
regimen is necessary.
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Wiley, R., Shelal,
Z., Bernard, C.,
Urbauer, D., Toy,
E., &
Ramondetta, L.
(2019). Teambased
learning module
for undergraduate
medical
education: A
module focused
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papilloma virus to
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willingness to
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A team-based
learning (TBL)
module focused on
HPV for first-year
medical students
about HPV will
better increase
knowledge and
likeliness to
vaccinate than
traditional education
methods.

239
students
were
invited to
participate
in the pretest survey
at
McGovern
Medical
School.
Ninetythree
students
responded
to the
initial
survey
(rate =
38.9%)
and of
those, 61
completed
the posttest
survey,

Qualitativ
e
Randmoiz
ed Study

Post-test
scores may be
inflated due to
recall bias
from the
recent
instruction of
HPV teaching
compared
with students
surveyed
across the
state. The
unknown of
how
knowledge
obtained in
medical
school will
translate into
future practice
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Wilson, A. R.,
Hashibe, M.,
Bodson, J., Gren,
L. H., Taylor, B.
A., Greenwood,
J., Jackson, B. R.,

To assess the
demographic and
attitudinal factors
associated with HPV
vaccine initiation
and completion

Two
groups of
women
ages 1826. 325
Surveys

Cross
Sectional
Survey

Limitations
identified
were
generalizabilit
y of the
current study.

Students showed
a significant
improvement in
general and
vaccine-related
HPV knowledge,
equal to the
knowledge
among graduating
medical seniors
across the state
and superior
specifically in the
case of vaccinerelated
knowledge.
Students made the
greatest gains in
knowledge
regarding which
cancers and
precancerous
diseases are
associated with
HPV, and general
knowledge of
high-risk HPV
Results of this
study illustrate
that awareness is
already high (near
saturation) in

Level
IV

It appears that a
dedicated active
learning module on
human papillomavirus
significantly improves
future medical
practitioners comfort
with HPV related
cancers and
willingness to
advocate for
vaccinations. As
medical schools are
training the physicians
that will be on the
front lines, working to
prevent HPV-related
disease, a dedicated
module on HPV, may
be one tool to help
increase uptake of
vaccinations.

Level
III

The implications of
these findings may
help inform policies
and interventions
focused on increasing
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She, R., Egger,
among 18-26 year
M. J., & Kepka,
old women in Utah.
D. (2016). Factors
related to HPV
vaccine uptake
and 3-dose
completion
among women in
a low vaccination
region of the
USA: An
observational
study. BMC
Women's Health,
16(1), 41-41.
https://doi.org/10.
1186/s12905-0160323-5

Complete
d. 1 dose
(n=204)
and 3 dose
(n=159)
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One of the
primary
limitations
was the low
survey return
rate. Even
after
incentivizing
a second wave
of survey
dissemination,
response rates
totaled well
under 30 %.

target populations
and other factors,
such as strong
and consistent
physician
recommendations
are more
pivotal in
increasing
likelihood of
vaccination.
Additionally,
findings indicate
the need for
discussions of
risk assessment
be tailored to the
young adult
population

HPV vaccination rates
among young women.
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